10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission File Number 001-37900

Everspin Technologies, Inc.

(Exact name of Registrant as specified in its Charter)

Delaware	26-2640654
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

5670 W. Chandler Boulevard, Suite 100

Chandler, Arizona 85226

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (480) 347-1111

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	MRAM	The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  ☒    NO  ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).    YES  ☒    NO  ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Small reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  ☐    NO  ☒

The number of shares of the Registrant’s Common Stock outstanding as of November 11, 2021 was 19,608,354.

Table of Contents

		Page
	PART I—FINANCIAL INFORMATION
Item 1.	Financial Statements	3
	Condensed Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020	3
	Condensed Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2021 and 2020 (unaudited)	4
	Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and 2020 (unaudited)	5
	Condensed Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 (unaudited)	6
	Notes to Condensed Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27
	PART II—OTHER INFORMATION
Item 1.	Legal Proceedings	29
Item 1A.	Risk Factors	29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	48
Item 3.	Defaults Upon Senior Securities	48
Item 4.	Mine Safety Disclosures	48
Item 5.	Other Information	48
Item 6.	Exhibits	49
EXHIBIT INDEX		49
SIGNATURES		51

In this Quarterly Report on Form 10-Q, “we,” “our,” “us,” “Everspin Technologies,” and “the Company” refer to Everspin Technologies, Inc. The Everspin logo and other trade names, trademarks or service marks of Everspin Technologies are the property of Everspin Technologies, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

2

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

EVERSPIN TECHNOLOGIES, INC.

Condensed Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

	September 30,		December 31,
	2021		2020
Assets
Current assets:
Cash and cash equivalents	$	14,558	$	14,599
Accounts receivable, net		10,629		7,607
Inventory		6,668		5,721
Prepaid expenses and other current assets		337		270
Total current assets		32,192		28,197
Property and equipment, net		951		1,946
Right-of-use assets		1,270		2,313
Other assets		488		73
Total assets	$	34,901	$	32,529
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	2,663	$	2,224
Accrued liabilities		2,523		2,232
Deferred revenue		1,382		—
Current portion of long-term debt		3,364		4,242
Operating lease liabilities		1,011		1,508
Other liabilities		36		31
Total current liabilities		10,979		10,237
Long-term debt, net of current portion		2,100		3,748
Operating lease liabilities, net of current portion		268		903
Long-term income tax liability		229		229
Total liabilities	$	13,576	$	15,117
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020		—		—
Common stock, $0.0001 par value per share; 100,000,000 shares authorized; 19,552,125 and 19,031,556 shares issued and outstanding as of September 30, 2021 and December 31, 2020		2		2
Additional paid-in capital		177,821		174,584
Accumulated deficit		(156,498)		(157,174)
Total stockholders’ equity		21,325		17,412
Total liabilities and stockholders’ equity	$	34,901	$	32,529

The accompanying notes are an integral part of these condensed financial statements.

3

EVERSPIN TECHNOLOGIES, INC.

Condensed Statements of Operations and Comprehensive Income (Loss)

(In thousands, except share and per share amounts)

(Unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Product sales	$	12,037	$	9,577	$	31,292	$	30,139
Licensing, royalty, patent, and other revenue		2,758		543		5,631		1,915
Total revenue		14,795		10,120		36,923		32,054
Cost of product sales		6,043		7,763		14,629		19,009
Cost of licensing, royalty, patent, and other revenue		304		28		665		174
Total cost of sales		6,347		7,791		15,294		19,183
Gross profit		8,448		2,329		21,629		12,871
Operating expenses:1
Research and development		3,105		2,579		8,901		8,383
General and administrative		2,996		2,549		8,177		7,797
Sales and marketing		1,272		912		3,304		3,071
Total operating expenses		7,373		6,040		20,382		19,251
Income (loss) from operations		1,075		(3,711)		1,247		(6,380)
Interest expense		(165)		(157)		(461)		(501)
Other (expense) income, net		(8)		(3)		(35)		60
Net income (loss) before income taxes		902		(3,871)		751		(6,821)
Income tax expense		(22)		(24)		(75)		(100)
Net income (loss) and comprehensive income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Net income (loss) per share attributable to common stockholders:
Basic	$	0.05	$	(0.21)	$	0.03	$	(0.37)
Diluted	$	0.04	$	(0.21)	$	0.03	$	(0.37)
Weighted average common shares used to compute net income (loss) per common share attributable to common stockholders:
Basic		19,511,132		18,942,163		19,296,241		18,705,149
Diluted		19,912,918		18,942,163		19,787,889		18,705,149
1Operating expenses include stock-based compensation as follows:
Research and development	$	428	$	182	$	874	$	538
General and administrative		434		657		1,224		1,888
Sales and marketing		165		71		376		207
Total stock-based compensation	$	1,027	$	910	$	2,474	$	2,633

The accompanying notes are an integral part of these condensed financial statements.

4

EVERSPIN TECHNOLOGIES, INC.

Condensed Statements of Stockholders’ Equity

(In thousands, except share and per share amounts)

(Unaudited)

	Nine Months Ended September 30, 2021
				Additional				Total
	Common Stock			Paid-In		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2020	19,031,556	$	2	$	174,584	$	(157,174)	$	17,412
Exercise of stock options	54,077		—		144		—		144
Issuance of common stock under stock incentive plans	136,709		—		364		—		364
Stock-based compensation expense	—		—		743		—		743
Net loss	—		—		—		(460)		(460)
Balance at March 31, 2021	19,222,342	$	2	$	175,835	$	(157,634)	$	18,203
Exercise of stock options	23,280		—		57		—		57
Issuance of common stock under stock incentive plans	189,652		—		92		—		92
Stock-based compensation expense	—		—		704		—		704
Net income	—		—		—		256		256
Balance at June 30, 2021	19,435,274	$	2	$	176,688	$	(157,378)	$	19,312
Exercise of stock options	27,386		—		106		—		106
Issuance of common stock under stock incentive plans	68,002		—		—		—		—
Stock-based compensation expense	—		—		1,027		—		1,027
Exercise of warrants	21,463				—		—		—
Net income	—		—		—		880		880
Balance at September 30, 2021	19,552,125	$	2	$	177,821	$	(156,498)	$	21,325

	Nine Months Ended September 30, 2020
				Additional				Total
	Common Stock			Paid-In		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2019	18,081,753	$	2	$	167,149	$	(148,662)	$	18,489
Issuance of common stock under stock incentive plans	88,375		—		315		—		315
Stock-based compensation expense	—		—		805		—		805
Issuance of common stock in at-the-market offering, net of issuance costs	468,427		—		2,084		—		2,084
Net loss	—		—		—		(1,732)		(1,732)
Balance at March 31, 2020	18,638,555	$	2	$	170,353	$	(150,394)	$	19,961
Issuance of common stock under stock incentive plans	231,220		—		827		—		827
Stock-based compensation expense	—		—		918		—		918
Net loss	—		—		—		(1,294)		(1,294)
Balance at June 30, 2020	18,869,775	$	2	$	172,098	$	(151,688)	$	20,412
Issuance of common stock under stock incentive plans	101,016		—		379		—		379
Stock-based compensation expense	—		—		910		—		910
Issuance of warrant	—		—		152		—		152
Net loss	—		—		—		(3,895)		(3,895)
Balance at September 30, 2020	18,970,791	$	2	$	173,539	$	(155,583)	$	17,958

The accompanying notes are an integral part of these condensed financial statements.

5

EVERSPIN TECHNOLOGIES, INC.

Condensed Statement of Cash Flows

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2021		2020
Cash flows from operating activities
Net income (loss)	$	676	$	(6,921)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		1,117		1,611
Stock-based compensation		2,474		2,633
Non-cash warrant revaluation		5		2
Non-cash interest expense		274		231
Changes in operating assets and liabilities:
Accounts receivable		(3,022)		(2,368)
Inventory		(947)		1,690
Prepaid expenses and other current assets		(67)		440
Other assets		(175)		—
Accounts payable		656		(31)
Accrued liabilities		655		(692)
Deferred revenue		1,382		—
Lease liabilities		(90)		(132)
Net cash provided by (used in) operating activities		2,938		(3,537)
Cash flows from investing activities
Purchases of property and equipment		(578)		(307)
Net cash used in investing activities		(578)		(307)
Cash flows from financing activities
Payments on long-term debt		(2,800)		—
Payments on finance lease obligation		—		(6)
Proceeds from exercise of stock options and purchase of shares in employee stock purchase plan		399		1,206
Proceeds from issuance of common stock in at-the-market offering, net of issuance costs		—		2,084
Net cash (used in) provided by financing activities		(2,401)		3,284
Net decrease in cash and cash equivalents		(41)		(560)
Cash and cash equivalents at beginning of period		14,599		14,487
Cash and cash equivalents at end of period	$	14,558	$	13,927
Supplementary cash flow information:
Interest paid	$	178	$	271
Operating cash flows paid for operating leases	$	1,212	$	1,298
Financing cash flows paid for finance leases	$	—	$	6
Non-cash investing and financing activities:
Increase of right-of-use asset and lease liability due to lease modification	$	—	$	545
Purchases of property and equipment in accounts payable and accrued liabilities	$	—	$	8
Bonus settled in shares of common stock	$	364	$	315
Issuance of warrant with debt	$	—	$	152

The accompanying notes are an integral part of these condensed financial statements.

6

EVERSPIN TECHNOLOGIES, INC.

Notes to Unaudited Condensed Financial Statements

1. Organization and Nature of Business

Everspin Technologies, Inc. (the Company) was incorporated in Delaware on May 16, 2008. The Company’s magnetoresistive random-access memory (MRAM) solutions offer the persistence of non-volatile memory with the speed and endurance of random-access memory (RAM) and enable the protection of mission critical data particularly in the event of power interruption or failure. The Company’s MRAM solutions allow its customers in the industrial, medical, automotive/transportation, aerospace and data center markets to design high performance, power efficient and reliable systems without the need for bulky batteries or capacitors.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information required by GAAP for complete financial statements. These unaudited interim condensed financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company’s financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any other future year.

The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the SEC.

The Company believes that its existing cash and cash equivalents as of September 30, 2021, coupled with its anticipated growth and sales levels will be sufficient to meet its anticipated cash requirements for at least the next twelve months from the financial statement issuance date. The Company’s future capital requirements will depend on many factors, including, among other things, its growth rate, the timing and extent of its spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the introduction of new products. The Company may be required at some point in the future to seek additional equity or debt financing, to sustain operations beyond that point, and such additional financing may not be available on acceptable terms or at all. If the Company is unable to raise additional capital or generate sufficient cash from operations to adequately fund its operations, it will need to curtail planned activities to reduce costs. Doing so will likely harm its ability to execute on its business plan.

Prior Period Reclassifications

Certain immaterial prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, fair value of assets and liabilities, inventory reserves, product warranty reserves, deferred tax assets and

7

related valuation allowances, and stock-based compensation. The Company believes its estimates and assumptions are reasonable; however, actual results may differ from the Company’s estimates.

Accounts receivable, net

The Company establishes an allowance for product returns. The Company analyzes historical returns, current economic trends and changes in customer demand and acceptance of products when evaluating the adequacy of sales returns. Returns are processed as credits on future purchases, and as a result, the allowance is recorded against the balance of trade accounts receivable. In addition, the Company establishes an allowance for estimated price concessions related to its distributor agreements. The Company estimates credits to distributors based on the historical rate of credits provided to distributors relative to sales.

Accounts receivable, net consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Trade accounts receivable	$	10,500	$	7,590
Unbilled accounts receivable		344		255
Allowance for product returns and price concessions		(215)		(238)
Accounts receivable, net	$	10,629	$	7,607

Concentration of Credit Risk

Financial instruments that potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents that are held by a financial institution in the United States and accounts receivable. Amounts on deposit with a financial institution may at times exceed federally insured limits. The Company maintains its cash accounts with high credit quality financial institutions and, accordingly, minimal credit risk exists with respect to the financial institutions.

Significant customers are those which represent more than 10% of the Company’s total revenue or net accounts receivable balance at each respective balance sheet date. For the purposes of this disclosure, the Company defines “customer” as the entity that is purchasing the products or licenses directly from the Company, which includes the distributors of the Company’s products in addition to end customers that the Company sells to directly. For each significant customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable, net are as follows:

	Revenue								Accounts Receivable, net
	Three Months Ended				Nine Months Ended				As of
	September 30,				September 30,				September 30,		December 31,
Customers	2021		2020		2021		2020		2021		2020
Customer A	17	%	38	%	14	%	32	%	21	%	29	%
Customer B	13	%	*		20	%	*		31	%	25	%
Customer C	*		*		*		*		12	%	*

* Less than 10%

Fair Value of Financial Instruments

Fair value is defined as an exit price, representing the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. The framework for measuring fair value provides a three-tier hierarchy prioritizing inputs to valuation techniques used in measuring fair value as follows:

Level 1— Observable inputs such as quoted prices for identical assets or liabilities in active markets;

Level 2— Inputs, other than quoted prices for identical assets or liabilities in active markets, which are observable either directly or indirectly; and

8

Level 3— Unobservable inputs in which there is little or no market data requiring the reporting entity to develop its own assumptions.

As of September 30, 2021, based on Level 2 inputs and the borrowing rates available to the Company for loans with similar terms and consideration of the Company’s credit risk, the carrying value of the Company’s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value. The Company’s financial instruments consist of Level 1 assets and a Level 3 liability. Level 1 assets consist of highly liquid money market funds that are included in cash equivalents. The Company’s Level 3 liability consists of warrants issued in connection with the Company’s current credit facility (Note 6).

The following tables sets forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	September 30, 2021
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,657	$	—	$	—	$	14,657
Total assets measured at fair value	$	14,657	$	—	$	—	$	14,657
Liabilities:
Warrant liability	$	—	$	—	$	36	$	36
Total liabilities measured at fair value	$	—	$	—	$	36	$	36

	December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,669	$	—	$	—	$	14,669
Total assets measured at fair value	$	14,669	$	—	$	—	$	14,669
Liabilities:
Warrant liability	$	—	$	—	$	31	$	31
Total liabilities measured at fair value	$	—	$	—	$	31	$	31

Recently Issued Pronouncements

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. As the Company is a smaller reporting company, ASU 2016-13 is effective for the Company’s annual reporting periods, and interim periods within those years, beginning after December 15, 2022, and requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements Financial Instruments-Credit Losses (Topic 326). The new ASU provides narrow-scope amendments to help apply ASU No. 2016-13. The Company is evaluating the impact of the adoption of ASU 2016-13 and ASU 2019-04 on its financial statements.

9

3. Revenue

The Company sells the majority of its products to distributors and original equipment manufacturers (OEMs). The Company also recognizes revenue under manufacturing and engineering service agreements and licensing and royalty agreements with some customers.

The following table presents the Company’s revenues disaggregated by sales channel (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Distributor	$	9,143	$	5,385	$	24,644	$	18,952
Non-distributor		5,652		4,735		12,279		13,102
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

The following table presents the Company’s revenues disaggregated by timing of recognition (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Point in time	$	13,618	$	9,756	$	34,212	$	30,982
Over time		1,177		364		2,711		1,072
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

The following table presents the Company’s revenues disaggregated by type (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Product sales	$	12,037	$	9,577	$	31,292	$	30,139
Royalties		274		179		1,612		843
Patents		1,307		—		1,307		—
Other revenue		1,177		364		2,712		1,072
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

In September 2021, the Company entered into an intellectual property monetization deal to sell five patents to a customer for a total contract value of $5.25 million. Two of the patents were assigned to the customer in September 2021, and the remaining three patents were assigned to the customer subsequent to quarter-end in October 2021. Control is transferred when the patents are assigned to the customer. As a result, $1.30 million of patent revenue was recognized during the quarter ended September 31, 2021, related to the patent sales, with the remaining $3.95 million to be recognized in the fourth quarter of 2021.

The Company recognizes revenue in three primary geographic regions: Asia-Pacific (APAC); North America; and Europe, Middle East and Africa (EMEA). The following table presents the Company’s revenues disaggregated by the geographic region to which the product is delivered or licensee is located (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
APAC	$	8,523	$	7,152	$	23,474	$	22,435
North America		4,197		2,109		8,623		5,033
EMEA		2,075		859		4,826		4,586
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

10

4. Balance Sheet Components

Inventory

Inventory consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Raw materials	$	356	$	329
Work-in-process		5,084		4,910
Finished goods		1,228		482
Total inventory	$	6,668	$	5,721

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Payroll-related expenses	$	1,994	$	1,274
Inventory		266		416
Other		263		542
Total accrued liabilities	$	2,523	$	2,232

Deferred Revenue

In the nine months ended September 30, 2021, the Company executed contractual arrangements with a customer for the development of a RAD-Hard product, consisting of a technology license, design license agreement and development subcontract. The Company does not share in the rights to future revenues or royalties. The total arrangements are for $6.5 million in consideration.

The Company concluded these contractual arrangements represent one arrangement and evaluated its promises to the customer and whether the performance obligations granted under the arrangement were distinct.  The licenses provided to the customer are not transferable, are of limited value without the promised development services, and the customer cannot benefit from the license agreements without the specific obligated services in the development subcontract, as there is strong interdependency between the licenses and the development subcontract. Accordingly, the Company determined the licenses were not distinct within the context of the contract and combined the license with other performance obligations.

As a result, the Company is recognizing revenue related to the performance obligations over time using the input method based on costs incurred to date relative to the total expected costs of the contract and began recognizing revenue in the second quarter of 2021 over the performance obligation period.

Under the agreements, the Company received a non-refundable, upfront payment of $3.0 million in the first quarter of 2021 and a payment of $0.7 million was received in the third quarter of 2021. As of September 30, 2021, $1.4 million was recorded as deferred revenue, current, with $0.9 million and $2.3 million recognized as revenue during the three and nine months ended September 30, 2021, respectively.

5. Leases

Operating leases consist primarily of office space expiring at various dates through 2023. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

11

The undiscounted future non-cancellable lease payments under the Company’s operating leases were as follows (in thousands):

As of September 30, 2021	Amount
2021	$	391
2022		861
2023		68
Total lease payments		1,320
Less: imputed interest		(41)
Total operating lease liabilities		1,279
Less: current portion of operating lease liabilities		(1,011)
Total operating lease liabilities, net of current portion	$	268

Other information related to the Company’s operating lease liabilities was as follows:

	September 30,		December 31,
	2021		2020
Weighted-average remaining lease term (years)	1.15		1.74
Weighted-average discount rate	6.00	%	6.00	%

In September 2021, and subsequent to quarter end in October 2021, the Company entered into two new office lease agreements for leases that were set to expire in the fourth quarter of 2021 and the first quarter of 2022. Both new lease agreements are scheduled to commence in February 2022. Monthly escalating lease payments range from $13,000 to $39,000, with maturity dates ranging from April 2027 – January 2029, both with options to extend upon written notice within twelve months prior to maturity.

6. Debt

2019 Credit Facility

In August 2019, the Company executed an Amended and Restated Loan and Security Agreement (2019 Credit Facility), which amended and restated the Company’s prior loan and security agreement (2017 Credit Facility), providing for a formula revolving line of credit (Line of Credit) and a term loan (2019 Term Loan) with Silicon Valley Bank (SVB) to refinance in full the outstanding principal balance of $8.0 million under the 2017 Credit Facility. In August 2019, the Company paid the final payment of $0.8 million, which was due upon the refinancing of the 2017 Credit Facility.

In July 2020, the Company executed the first amendment to the 2019 Credit Facility with SVB. The amendment, among other things, extended the initial 12-month interest-only period for the 2019 Term Loan to a 16-month interest-only period and lowered the floor interest rate. The floor interest rates for the 2019 Term Loan and the Line of Credit were reduced from 4.75% and 6.75% to 3.75% and 4.75%, respectively.

The amended Line of Credit allows for a maximum draw of $5.0 million, subject to a formula borrowing base, has a two-year term and bears interest at a floating rate equal to the Wall Street Journal (WSJ) prime rate plus 1.5%, per annum, subject to a floor of 4.75%. As of September 30, 2021, the interest rate was 4.75%. The Line of Credit required a commitment fee of 1.6% of the maximum availability of the Line of Credit, which was paid in August 2019 upon closing, and was accounted for as a debt discount. The Line of Credit also provides for a termination fee equal to 1% of the maximum availability under the Line of Credit, which is due in case of a termination of the Line of Credit prior to the scheduled maturity date, and an unused facility fee equal to 0.125% per annum of the average unused portion of the Line of Credit, which is expensed as incurred. At execution, $2.0 million from the Line of Credit was used to refinance a portion of the outstanding balance of the 2017 Credit Facility, and $3.0 million remains available under the Line of Credit, subject to borrowing base availability. As of September 30, 2021, the effective interest rate under the Line of Credit was 10.18% and the outstanding balance was $1.0 million. The Line of Credit was set to mature on August 5, 2021. The second amendment, entered into on July 28, 2021, extended the maturity date of the Line of Credit to August 5, 2022.

12

The amended 2019 Term Loan provides for a $6.0 million term loan, which was used to refinance the remaining balance of the 2017 Credit Facility. The 2019 Term Loan has a term of 46 months, and a 16-month interest-only period followed by 30 months of equal principal payments, plus accrued interest. The 2019 Term Loan bears interest at a floating rate equal to the WSJ prime rate minus 0.75%, subject to a floor of 3.75%. As of September 30, 2021, the interest rate was 3.75%. A final payment of 7% of the original principal amount of the 2019 Term Loan must be made when the 2019 Term Loan is prepaid or repaid, whether at maturity or as a result of a prepayment or acceleration or otherwise. The additional payment, which is accounted for as a debt discount, is being accreted using the effective interest method. The 2019 Term Loan has a prepayment fee equal to 2% of the total commitment, which is due only if the 2019 Term Loan is prepaid prior to the scheduled maturity date for any reason. As of September 30, 2021, the effective interest rate under the 2019 Term Loan was 7.85% and the outstanding balance was $4.6 million. The 2019 Term Loan matures on June 1, 2023.

In conjunction with entering into the 2019 Credit Facility, on August 5, 2019, the Company and SVB amended and restated the warrant issued to SVB in connection with the first amendment to the 2017 Credit Facility, which was a warrant to purchase 9,375 shares of the Company’s common stock at an exercise price of $8.91 per share, to add an option by SVB to put the warrant back to the Company for $50,000 upon expiration or a liquidity event, to be prorated if SVB exercises a portion of the warrant. The warrant expires on July 6, 2023. The warrant is classified as a liability and recorded at fair value within other liabilities in the Company’s condensed balance sheet. Due to the put right, the warrant is subject to fair value remeasurement at each subsequent reporting date until the exercise or expiration of the warrant. Any resulting change in the fair value of the warrant will be recorded as other (expense) income, net in the Company’s condensed statement of operations and comprehensive loss. The Company recognized other expense of $0 and $5,000 for the three and nine months ended September 30, 2021, respectively. The Company recognized other expense of $5,000 and $2,000 for the three and nine months ended September 30, 2020, respectively.

In conjunction with entering into the first amendment to the 2019 Credit Facility, on July 15, 2020, the Company issued a warrant to SVB to purchase 21,500 shares of the Company’s common stock at an exercise price of $0.01 per share. The warrant expires on July 15, 2025. The warrant is classified as equity and was recorded as a debt discount that will be amortized to interest expense using the effective interest method. The fair value of the warrant was $152,000 on the date of issuance using the Black-Scholes option-pricing model. On July 22, 2021, SVB elected to exercise the warrant associated with the first amendment to the 2019 Credit Facility, which resulted in a net cashless exercise of the warrant and the issuance of 21,463 shares of the Company’s common stock.

Collateral for the 2019 Credit Facility includes all of the Company’s assets except for intellectual property. The Company is required to comply with certain covenants under the 2019 Credit Facility, including requirements to maintain a minimum cash balance and availability under the Line of Credit, and restrictions on certain actions without the consent of the lender, such as limitations on its ability to engage in mergers or acquisitions, sell assets, incur indebtedness or grant liens or negative pledges on its assets, make loans or make other investments. Under these covenants, the Company is prohibited from paying cash dividends with respect to its capital stock. The Company was in compliance with all covenants at September 30, 2021. The 2019 Credit Facility contains a material adverse effect clause which provides that an event of default will occur if, among other triggers, an event occurs that could reasonably be expected to result in a material adverse effect on the Company’s business, operations or condition, or on the Company’s ability to perform its obligations under the 2019 Term Loan. As of September 30, 2021, management does not believe that it is probable that the clause will be triggered within the next 12 months, and therefore the 2019 Term Loan is classified as long-term debt.

The amortization of the debt issuance costs and accretion of the debt discount is included in interest expense within the statement of operations and comprehensive loss and included in non-cash interest expense within the statement of cash flows.

The carrying value of the Company’s 2019 Credit Facility as of September 30, 2021 was as follows (in thousands):

	Current		Long-Term
	Portion		Debt		Total
Credit Facility	$	3,400	$	2,220	$	5,620
Unamortized debt discounts		(36)		(120)		(156)
Net carrying value	$	3,364	$	2,100	$	5,464

13

The carrying value of the Company’s 2019 Credit Facility as of December 31, 2020 was as follows (in thousands):

	Current		Long-Term
	Portion		Debt		Total
Credit Facility	$	4,400	$	4,020	$	8,420
Unamortized debt discounts		(158)		(272)		(430)
Net carrying value	$	4,242	$	3,748	$	7,990

The table below includes the principal repayments due under the 2019 Credit Facility (in thousands):

	Principal Repayment as of September 30, 2021
2021 (three remaining months)		600
2022		3,400
2023		1,620
Total principal repayments	$	5,620

The $0.6 million in principal repayments noted above for the three remaining months for the year ended December 31, 2021 are related to payments on the Term Loan.

Of

7. Stockholders’ Equity

At-the-Market Sales Agreement

In August 2019, the Company entered into an Open Market Sale Agreement (2019 Sales Agreement) with Jefferies, LLC (Jefferies), for the offer and sale of shares of its common stock having an aggregate offering of up to $25.0 million from time to time through Jefferies, acting as the Company’s sales agent. The issuance and sale of these shares by the Company pursuant to the 2019 Sales Agreement are deemed an “at-the-market” (ATM) offering under the Securities Act of 1933, as amended. Under the 2019 Sales Agreement, the Company agreed to pay Jefferies a commission of up to 3% of the gross proceeds of any sales made pursuant to the Sales Agreement. During the nine months ended September 30, 2020, the Company received net proceeds of $2.1 million, after deducting commissions and expenses payable by the Company, from the sale of 468,427 shares of common stock pursuant to the 2019 Sales Agreement. The Company suspended sales under the 2019 Sales Agreement in March 2020 and terminated the ATM program in November 2020.

8. Stock-Based Compensation

The following table summarizes the stock option and award activity for the nine months ended September 30, 2021:

		Options Outstanding
			Weighted-		Weighted-
	Options and		Average		Average	Aggregate
	Awards		Exercise		Remaining	Intrinsic
	Available for	Number of	Price Per		Contractual	Value
	Grant	Options	Share		Life (years)	(In thousands)
Balance—December 31, 2020	179,219	2,272,905	$	5.58	7.9	$	1,640
Authorized	1,120,946
RSUs granted	(517,564)
RSUs cancelled/forfeited	108,581
Options granted	(744,978)	744,978	$	5.60
Options exercised	—	(104,743)	$	2.94		$	346
Options cancelled/forfeited	897,471	(916,911)	$	6.49
Balance—September 30, 2021	1,043,675	1,996,229	$	5.30	8.3	$	2,951
Options exercisable—September 30, 2021		760,979	$	6.01	6.8	$	895

14

The total grant date fair value of options vested was $178,000 and $438,000 during the three months ended September 30, 2021 and 2020, respectively, and $711,000 and $1.8 million during the nine months ended September 30, 2021 and 2020, respectively.

The weighted-average grant date fair value of employee options granted was $3.59 and $3.62 per share during the three months ended September 30, 2021 and 2020, respectively, and $3.58 and $1.71 per share during the nine months ended September 30, 2021 and 2020, respectively.

As of September 30, 2021, of the 916,911 options cancelled/forfeited, 19,440 of the options relate to a prior stock-based compensation plan that are no longer available for grant under the current stock-based compensation plan.

2016 Employee Stock Purchase Plan

In January 2021, there was an increase of 190,315 shares reserved for issuance under the Company’s Employee Stock Purchase Plan (ESPP) pursuant to the terms of the ESPP. The Company had 684,996 shares available for future issuance under the Company’s ESPP as of September 30, 2021. Employees purchased 32,186 shares for $92,000 during the nine months ended September 30, 2021. Employees purchased 22,474 shares for $50,000 during the three and nine months ended September 30, 2020.

Restricted Stock Units

The following table summarizes restricted stock units (RSUs) activity for the nine months ended September 30, 2021:

	RSUs Outstanding
		Weighted-
		Average
	Number of	Grant Date
	Restricted Stock	Fair Value Per
	Units	Share
Balance—December 31, 2020	416,742	$	4.89
Granted	517,564	$	5.51
Vested	(362,438)	$	5.62
Cancelled/forfeited	(108,581)	$	4.75
Balance—September 30, 2021	463,287	$	5.05

The fair value of RSUs is determined on the date of grant based on the market price of the Company’s common stock on that date. As of September 30, 2021, there was $1.9 million of unrecognized stock-based compensation expense related to RSUs to be recognized over a weighted-average period of 2.2 years.

Stock-based Compensation Expense

As of September 30, 2021, there was $3.5 million of total unrecognized stock-based compensation expense related to unvested options which is expected to be recognized over a weighted-average period of 3.0 years.

9. Significant Agreements

GLOBALFOUNDRIES, Inc. Joint Development Agreement

Since October 17, 2014, the Company has participated in a joint development agreement (JDA) with GLOBALFOUNDRIES Inc. (GF), a semiconductor foundry, for the joint development of Spin-transfer Torque MRAM (STT-MRAM), technology to produce a family of discrete and embedded MRAM technologies. The term of the agreement is until the completion, termination, or expiration of the last statement of work entered into pursuant to the joint development agreement. The Company entered into a Statement of Work (SOW) and an Amendment to the SOW, under the JDA with GF effective August 2016 and June 2018, respectively. The agreement was extended on December 31, 2019 to include a new phase of support for 12nm MRAM development.

15

Under the current JDA extension terms, each party licenses its relevant intellectual property to the other party. For certain jointly developed works, the parties have agreed to follow an invention allocation procedure to determine ownership. In addition, GF possesses the exclusive right to manufacture the Company’s discrete and embedded STT-MRAM devices developed pursuant to the agreement until the earlier of three years after the qualification of the MRAM device for a particular technology node or four years after the completion of the relevant statement of work under which the device was developed. For the same exclusivity period associated with the relevant device, GF agreed not to license intellectual property developed in connection with the JDA to named competitors of the Company.

Generally, unless otherwise specified in the agreement or a statement of work, the Company and GF share project costs, which do not include personnel or production qualification costs, under the JDA. If GF manufactures, sells or transfers to customers wafers containing production quantified STT-MRAM devices that utilize certain design information, GF will be required to pay the Company a royalty.

Silterra Malaysia Sdn. Bhd. Joint Collaboration Agreement

In September 2018, the Company entered into a Joint Collaboration Agreement (JCA) with Silterra Malaysia Sdn. Bhd., and another third party. The JCA will create additional manufacturing capacity for the Company’s Toggle MRAM products. The Company had previously anticipated initial production starting in 2020. However, as a result of recent delays, the Company now anticipates initial production to start some time in 2022. Under the JCA, the Company is required to pay non-recurring engineering costs of $1.0 million. As of September 30, 2021, the Company has paid $600,000 of these JCA costs. There were no JCA costs paid during the nine months ended September 30, 2021. Subsequent to September 30, 2021, on October 23, 2021, the Company executed a termination of the JCA. As a result, the Company does not expect to incur additional JCA costs for the remainder of 2021.

10. Net Income (Loss) Per Common Share

Basic earnings per share is calculated by dividing net income by the weighted average shares outstanding. Diluted earnings per share is calculated using the treasury stock method by dividing net income by the total weighted average shares of common stock outstanding in addition to the potential impact of dilutive securities including restricted stock units, warrants, and options.

The following tables set forth the computation of basic and diluted net income (loss) per share attributable to common stockholders (in thousands, except share and per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Numerator:
Net income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Denominator:
Weighted-average common shares outstanding used to calculate net income (loss) per common share, basic		19,511,132		18,942,163		19,296,241		18,705,149
Net income (loss) per common share, basic	$	0.05	$	(0.21)	$	0.03	$	(0.37)

16

	Three Months Ended September 30,				Nine Months Ended September 30,
	September 30,				September 30,
	2021		2020		2021		2020
Numerator:
Net income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Denominator:
Weighted-average common shares outstanding used to calculate net income (loss) per common share, basic		19,511,132		18,942,163		19,296,241		18,705,149
Effect of dilutive		401,786		—		491,648		—
Weighted-average common shares outstanding used to calculate net income (loss) per common share, diluted		19,912,918		18,942,163		19,787,889		18,705,149
Net income (loss) per common share, diluted	$	0.04	$	(0.21)	$	0.03	$	(0.37)

The following outstanding shares of potentially dilutive securities have been excluded from diluted net income (loss) per common share for the periods presented, because their inclusion would be anti-dilutive:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2021	2020	2021	2020
Options to purchase common stock	1,251,209	2,300,452	1,277,088	2,300,452
RSUs	6,437	458,324	28,389	458,324
Common stock warrants	9,375	49,336	9,375	49,336
ESPP	14,031	—	28,078	—
Total	1,281,052	2,808,112	1,342,930	2,808,112

17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes included in Part I, Item 1 of this report and with our audited financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2020.

Forward-Looking Statements

This discussion contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Forward-looking statements are identified by words such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other “forward-looking” information. These statements relate to our future plans, strategies, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in Part II, Item 1A — “Risk Factors,” and elsewhere in this report, as well as in our other filings with the Securities and Exchange Commission (SEC). Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

Overview

Everspin is a pioneer in the successful commercialization of Magnetoresistive Random Access Memory (MRAM) technology. Our portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), is delivering superior performance, persistence and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. With over 10 years of MRAM technology and manufacturing leadership, our memory solutions deliver significant value to our customers in key markets such as industrial, medical, automotive/transportation, aerospace and data center. We are the leading supplier of discrete MRAM components and a successful licensor of our broad portfolio of related technology intellectual property.

We sell our products directly and through our established distribution channels to industry-leading original equipment manufacturers (OEMs) and original design manufacturers (ODMs).

We manufacture our MRAM products using both captive and third-party manufacturing capabilities. We purchase industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes our magnetic-bit technology at our 200mm fabrication facility in Chandler, Arizona. We also manufacture full-flow 300mm CMOS wafers with our STT-MRAM magnetic-bit technology integrated in BEOL as part of our strategic relationship with GLOBALFOUNDRIES.

Key Metrics

We monitor a variety of key financial metrics to help us evaluate trends, establish budgets, measure the effectiveness of our business strategies and assess operational efficiencies. These financial metrics include revenue, gross margin, operating expenses and operating income determined in accordance with GAAP. Additionally, we monitor and project cash flow to determine our sources and uses for working capital to fund our operations. We also monitor Adjusted EBITDA, a non-GAAP financial measure, and design wins. We define Adjusted EBITDA as net income or loss adjusted for interest expense, taxes, depreciation and amortization, stock-based compensation expense, and restructuring costs, if any.

Adjusted EBITDA. Our management and board of directors use Adjusted EBITDA to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short-term and long-term operating and financing plans. Accordingly, we believe that Adjusted EBITDA provides useful information for investors

18

in understanding and evaluating our operating results in the same manner as our management and our board of directors. Adjusted EBITDA is a non-GAAP financial measure and should be considered in addition to, not as superior to, or as a substitute for, net income (loss) reported in accordance with GAAP. The following table presents a reconciliation of net income (loss), the most directly comparable GAAP measure, to Adjusted EBITDA for the periods indicated:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Adjusted EBITDA reconciliation:
Net income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Depreciation and amortization		361		799		1,117		1,611
Stock-based compensation expense		1,027		910		2,474		2,633
Interest expense		165		157		461		501
Income tax expense		22		24		75		100
Adjusted EBITDA	$	2,455	$	(2,005)	$	4,803	$	(2,076)

Design wins. To continue to grow our revenue, we must continue to achieve design wins for our MRAM products. We consider a design win to occur when an OEM or contract manufacturer notifies us that it has qualified one of our products as a component in a product or system for production. Because the life cycles for our customers’ products can last for many years, if these products have successful commercial introductions, we expect to continue to generate revenues over an extended period of time for each successful design win. New design wins in the first three quarters of 2021 were 40, 37, and 40, respectively, compared to 37, 43, and 52 in the first three quarters of 2020, respectively.

Effect of the COVID-19 Pandemic on our Business

The novel coronavirus (COVID-19) outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, “shelter-in-place,” “stay-at-home,” total lock-down orders, business limitations or shutdowns and similar orders. More recently, many new agencies have reported the spread of new variants of COVID-19, such as the Delta variant, that are more contagious than previous strains. The spread of these new strains is causing many government authorities to reimplement the aforementioned measures to try to reduce the spread that had become less prevalent. The COVID-19 pandemic and its variants have negatively impacted the global economy, disrupted global supply chains and workforce participation, and initially created significant volatility and disruption of financial markets.

Overall, our business remains operational in the midst of the pandemic. However, as a result of the ongoing COVID-19 outbreak and the related responses from government authorities, our business, results of operations and financial condition have been, and continue to be, adversely impacted. For example, we have experienced electronics supply chain and demand disruptions from extended factory shutdowns, particularly in some Asian countries, which created unusual order patterns, and subsequently slowed Toggle MRAM demand, particularly from our industrial customers. We continue to see an impact as reflected in reduced demand from some customers and distributors. While we are working closely with our manufacturing partners and suppliers to support demand for our products, the full impact on our demand from customers remains unknown. Management is thus planning for a broad range of possible demand outcomes in an effort to ensure the success of our business under a variety of end market conditions.

Further, in an effort to protect the health and safety of our employees, we transitioned most of our office and support employees and contractors to working from home; suspended all non-essential business travel; and implemented social distancing guidelines for our employees and contractors who must work in our manufacturing and laboratory locations. Consequently, the remote working environment we have implemented for our employees has adversely impacted manufacturing operations given delays in data gathering, analysis and inefficiencies of teams solving technical problems via remote-only means, which has impacted, and continues to impact, our cost of sales.

The emergence of the significantly more contagious Delta variant of COVID-19 and the prevalence of breakthrough cases of infection among fully vaccinated people adds additional uncertainty and could result in further impacts to our business and operations, including those discussed above and in “Risk Factors” in Part II, Item 1A of this report.

19

We will continue to monitor the situation and take additional actions as warranted. These actions may include further altering our operations in order to protect the best interests of our employees, customers and suppliers, and to comply with government requirements, while also planning and executing our business to best support our customers, suppliers, and partners.

The ultimate extent of the impact of the COVID-19 pandemic on our business, results of operations and financial condition will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the emergence and severity of its variants, the actions to contain the virus or treat its impact, such as the availability and efficacy of vaccines (particularly with respect to emerging strains of the virus) and potential hesitancy to use them, and how quickly and to what extent normal economic and operating conditions can resume. Accordingly, our current results and financial condition discussed herein may not be indicative of future operating results and trends. See “Risk Factors” in Part II, Item 1A of this report for additional risks we face due to the COVID-19 pandemic.

Results of Operations

The following table sets forth our results of operations for the periods indicated:

	Three Months Ended September 30,										Nine Months Ended September 30,
	2021		2020		2021			2020			2021		2020		2021			2020
	(In thousands)				(As a percentage of revenue)						(In thousands)				(As a percentage of revenue)
Product sales	$	12,037	$	9,577		81	%		95	%	$	31,292	$	30,139		85	%		94	%
Licensing, royalty, patent, and other revenue		2,758		543		19			5			5,631		1,915		15			6
Total revenue		14,795		10,120		100			100			36,923		32,054		100			100
Cost of product sales		6,043		7,763		41			77			14,629		19,009		40			59
Cost of licensing, royalty, patent, and other revenue		304		28		2			—			665		174		2			1
Total cost of sales		6,347		7,791		43			77			15,294		19,183		41			60
Gross profit		8,448		2,329		57			23			21,629		12,871		59			40
Operating expenses:
Research and development		3,105		2,579		21			25			8,901		8,383		24			26
General and administrative		2,996		2,549		20			25			8,177		7,797		22			24
Sales and marketing		1,272		912		9			9			3,304		3,071		9			10
Total operating expenses		7,373		6,040		50			59			20,382		19,251		55			60
Income (loss) from operations		1,075		(3,711)		7			(37)			1,247		(6,380)		4			(20)
Interest expense		(165)		(157)		(1)			(2)			(461)		(501)		(1)			(2)
Other (expense) income, net		(8)		(3)		—			—			(35)		60		—			—
Net income (loss) before income taxes		902		(3,871)		6			(38)			751		(6,821)		2			(21)
Income tax expense		(22)		(24)		—			—			(75)		(100)		—			—
Net income (loss) and comprehensive income (loss)	$	880	$	(3,895)		6	%		(39)	%	$	676	$	(6,921)		3	%		(22)	%

20

Comparison of the three months ended September 30, 2021 and 2020

Revenue

We generated 62% and 53% of our revenue from products sold through distributors for the three months ended September 30, 2021 and 2020, respectively.

In addition to selling our products to our distributors, we maintain a direct selling relationship, for strategic purposes, with several key customer accounts. We have organized our sales team and representatives into three primary regions: North America; Europe, Middle East and Africa (EMEA); and Asia-Pacific (APAC). We recognize revenue by geography based on the region in which our products are sold, and not to where the end products in which they are assembled are shipped. Our revenue by region for the periods indicated was as follows (in thousands):

	Three Months Ended September 30,
	2021		2020
APAC	$	8,523	$	7,152
North America		4,197		2,109
EMEA		2,075		859
Total revenue	$	14,795	$	10,120

	Three Months Ended
	September 30,				Change
	2021		2020		Amount		%
	(Dollars in thousands)
Product sales	$	12,037	$	9,577	$	2,460	25.7	%
Licensing, royalty, patent, and other revenue		2,758		543		2,215	407.9	%
Total revenue	$	14,795	$	10,120	$	4,675	46.2	%

Total revenue increased by $4.7 million, or 46.2%, from $10.1 million during the three months ended September 30, 2020 to $14.8 million during the three months ended September 30, 2021. Product sales increased by $2.5 million, or 25.7%, from $9.6 million to $12.0 million due to a higher volume of units produced and sold.

Licensing, royalty, and other revenue is a highly variable revenue item characterized by a small number of transactions annually with revenue based on size and terms of each transaction. Our best estimate of royalty revenue earned is made through the year, with an annual adjustment recognized for actual sales in the first quarter of each fiscal year. Licensing, royalty and other revenue increased by $2.2 million, from $0.5 million during the three months ended September 30, 2020 to $2.8 million during the three months ended September 30, 2021. The increase was driven by the sale of two patents during the quarter in a strategic effort to continue to monetize the Company’s intellectual property, along with an increase in licensing revenue from our contracts related to a U.S. Government RAD-Hard program entered into in the first quarter of 2021.

Cost of Sales and Gross Margin

	Three Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
Cost of product sales	$	6,043		$	7,763		$	(1,720)	(22.2)	%
Cost of licensing, royalty, patent, and other revenue		304			28			276	985.7	%
Total cost of sales	$	6,347		$	7,791		$	(1,444)	(18.5)	%
Gross margin		60.7	%		43.9	%

Cost of product sales decreased by $1.7 million, or 22.2%, from $7.8 million during the three months ended September 30, 2020, to $6.0 million during the three months ended September 30, 2021. The decrease was due to improved manufacturing yields, a reduction in charges to state inventory at its net realizable value, and accelerated depreciation adjustment for the three months ended September 30, 2020.

21

Cost of licensing, royalty, and other increased by $0.3 million from $28,000 during the three months ended September 30, 2020, to $0.3 million during the three months ended September 30, 2021. The increase was due primarily to increases in foundry and licensing activities.

Gross margin increased from 43.9% during the three months ended September 30, 2020 to 60.7% during the three months ended September 30, 2021. The increase in gross margin was due primarily to higher licensing and royalty revenue along with improved manufacturing yields.

Operating Expenses

Our operating expenses consist of research and development, general and administrative and sales and marketing expenses. Personnel-related expenses, including salaries, benefits, bonuses and stock-based compensation, are among the most significant component of each of our operating expense categories.

Research and Development Expenses. Our research and development expenses consist primarily of personnel-related expenses for the design and development of our products and technologies, development wafers required to validate and characterize our technology, and expenses associated with our joint development activities. Research and development expenses also include consulting services, circuit design costs, materials and laboratory supplies, fabrication and new packaging technology, and an allocation of related facilities and equipment costs. We recognize research and development expenses as they are incurred.

	Three Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
Research and development	$	3,105		$	2,579		$	526	20.4	%
Research and development as a % of revenue		21	%		25	%

Research and development expenses increased by $0.5 million, or 20.4%, from $2.6 million during the three months ended September 30, 2020 to $3.1 million during the three months ended September 30, 2021. The increase was primarily due to higher expenses relating to the development of our 28nm product.

	Three Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
General and administrative	$	2,996		$	2,549		$	447	17.5	%
General and administrative as a % of revenue		20	%		25	%

General and Administrative Expenses. General and administrative expenses increased by $0.5 million, or 17.5%, from $2.5 million during the three months ended September 30, 2020 to $3.0 million during the three months ended September 30, 2021. The increase is due primarily to profit sharing and professional service fees.

	Three Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
Sales and marketing	$	1,272		$	912		$	360	39.5	%
Sales and marketing as a % of revenue		9	%		9	%

Sales and Marketing Expenses. Sales and marketing expenses increased by $0.4 million, or 39.5%, from $0.9 million during the three months ended September 30, 2020 to $1.3 million during the three months ended September 30, 2021. The increase is due to an increase in variable compensation costs.

22

Interest Expense

	Three Months Ended
	September 30,				Change
	2021		2020		Amount		%
	(Dollars in thousands)
Interest expense	$	165	$	157	$	8	5.1	%

Interest expense increased by $8,000, or 5.1%, from $157,000 during the three months ended September 30, 2020 to $165,000 during the three months ended September 30, 2021. The increase was due to fees paid to extend the Line of Credit during the third quarter of 2021.

Other (Expense) Income, Net

	Three Months Ended
	September 30,				Change
	2021		2020		Amount		%
	(Dollars in thousands)
Other (expense) income, net	$	(8)	$	(3)	$	(5)	166.7	%

Other (expense) income, net was expense amounting to $3,000 during the three months ended September 30, 2020 compared to an expense of $8,000 during the three months ended September 30, 2021. The change was primarily due to a decrease in interest income earned on our cash balances during the quarter from the lower interest rate environment, offset by increases in tax payments.

Comparison of the nine months ended September 30, 2021 and 2020

Revenue

We generated 67% and 59% of our revenue from products sold through distributors for the nine months ended September 30, 2021 and 2020, respectively.

In addition to selling our products to our distributors, we maintain a direct selling relationship, for strategic purposes, with several key customer accounts. We have organized our sales team and representatives into three primary regions: North America; Europe, Middle East and Africa (EMEA); and Asia-Pacific (APAC). We recognize revenue by geography based on the region in which our products are sold, and not to where the end products in which they are assembled are shipped. Our revenue by region for the periods indicated was as follows (in thousands):

	Nine Months Ended September 30,
	2021		2020
APAC	$	23,474	$	22,435
North America		8,623		5,033
EMEA		4,826		4,586
Total revenue	$	36,923	$	32,054

	Nine Months Ended
	September 30,				Change
	2021		2020		Amount		%
	(Dollars in thousands)
Product sales	$	31,292	$	30,139	$	1,153	3.8	%
Licensing, royalty, patent, and other revenue		5,631		1,915		3,716	194.0	%
Total revenue	$	36,923	$	32,054	$	4,869	15.2	%

Total revenue increased by $4.9 million, or 15.2%, from $32.1 million during the nine months ended September 30, 2020 to $36.9 million during the nine months ended September 30, 2021. Product sales increased by $1.2 million, or 3.8%, from $30.1 million to $31.3 million due to a higher volume of units produced and sold.

23

Licensing, royalty, and other revenue is a highly variable revenue item characterized by a small number of transactions annually with revenue based on size and terms of each transaction. Our best estimate of royalty revenue earned is made through the year, with an annual adjustment recognized for actual sales in the first quarter of each fiscal year. Licensing, royalty and other revenue increased by $3.7 million, from $1.9 million during the nine months ended September 30, 2020 to $5.6 million during the nine months ended September 30, 2021. The increase was driven by the sale of two patents during the quarter in a strategic effort to continue to monetize the Company’s intellectual property, along with an increase in licensing revenue from our contracts related to a U.S. Government RAD-Hard program entered into in the second quarter of 2021.

Cost of Sales and Gross Margin

	Nine Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
Cost of product sales	$	14,629		$	19,009		$	(4,380)	(23.0)	%
Cost of licensing, royalty, patent, and other revenue		665			174			491	282.2	%
Total cost of sales	$	15,294		$	19,183		$	(3,889)	(20.3)	%
Gross margin		58.6	%		40.2	%

Cost of product sales decreased by $4.6 million, or 23.7%, from $19.2 million during the nine months ended September 30, 2020, to $14.6 million during the nine months ended September 30, 2021. The decrease was due to improved manufacturing yields, along wit ha one-time non-cash inventory reserve and accelerated depreciation adjustment for the nine months ended September 30, 2020.

Cost of licensing, royalty, and other increased by $0.5 from $0.2 million during the nine months ended September 30, 2020, to $0.7 million during the nine months ended September 30, 2021. The increase was due primarily to increases in foundry and licensing activities.

Gross margin increased from 40.2% during the nine months ended September 30, 2020 to 58.2% during the nine months ended September 30, 2021. The increase in gross margin was due primarily to higher licensing and royalty revenue along with improved manufacturing yields.

Operating Expenses

Our operating expenses consist of research and development, general and administrative and sales and marketing expenses. Personnel-related expenses, including salaries, benefits, bonuses and stock-based compensation, are among the most significant component of each of our operating expense categories.

Research and Development Expenses. Our research and development expenses consist primarily of personnel-related expenses for the design and development of our products and technologies, development wafers required to validate and characterize our technology, and expenses associated with our joint development activities. Research and development expenses also include consulting services, circuit design costs, materials and laboratory supplies, fabrication and new packaging technology, and an allocation of related facilities and equipment costs. We recognize research and development expenses as they are incurred.

	Nine Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
Research and development	$	8,901		$	8,383		$	518	6.2	%
Research and development as a % of revenue		24	%		26	%

24

Research and development expenses increased by $0.5 million, or 6.2%, from $8.4 million during the nine months ended September 30, 2020 to $8.9 million during the nine months ended September 30, 2021. The increase was primarily due to higher expenses relating to the development of our 28 nm product.

	Nine Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
General and administrative	$	8,177		$	7,797		$	380	4.9	%
General and administrative as a % of revenue		22	%		24	%

General and Administrative Expenses. General and administrative expenses increased by $0.4 million, or 4.9%, from $7.8 million during the nine months ended September 30, 2020 to $8.2 million during the nine months ended September 30, 2021. The increase is due primarily to profit sharing and professional service fees.

	Nine Months Ended
	September 30,						Change
	2021			2020			Amount		%
	(Dollars in thousands)
Sales and marketing	$	3,304		$	3,071		$	233	7.6	%
Sales and marketing as a % of revenue		9	%		10	%

Sales and Marketing Expenses. Sales and marketing expenses increased by $0.2 million or 7.6%, from $3.1 million during the nine months ended September 30, 2020 to $3.3 million during the nine months ended September 30, 2021. The increase is due to an increase in variable compensation costs.

Interest Expense

	Nine Months Ended
	September 30,				Change
	2021		2020		Amount		%
	(Dollars in thousands)
Interest expense	$	461	$	501	$	(40)	(8.0)	%

Interest expense decreased by $40,000 or 8.0%, from $501,000 during the nine months ended September 30, 2020 to $461,000 during the nine months ended September 30, 2021. The decrease was partially due to a decrease in outstanding principal on our Term Loan during the first three quarters of 2021.

Other (Expense) Income, Net

	Nine Months Ended
	September 30,				Change
	2021		2020		Amount		%
	(Dollars in thousands)
Other (expense) income, net	$	(35)	$	60	$	(95)	(158.3)	%

Other (expense) income, net was income of $60,000 during the nine months ended September 30, 2020 compared to an expense of $35,000 during the nine months ended September 30, 2021. The change was primarily due to a decrease in interest income earned on our cash balances during the quarter from the lower interest rate environment.

Liquidity and Capital Resources

We have generated significant losses since our inception and had an accumulated deficit of $156.5 million as of September 30, 2021, compared to $157.2 million as of December 31, 2020. We have historically financed our operations primarily through the sale of our common stock in our initial public offering (IPO) and follow-on public offering, sales of our common stock under our at-the-market (ATM) program (which was terminated in November 2020), sales of our redeemable convertible preferred stock, debt financing and the sale of our products. As of September 30, 2021, we had $14.6 million of cash and cash equivalents, compared to $14.6 million as of December 31, 2020.

25

We believe that our existing cash and cash equivalents as of September 30, 2021, coupled with the amount available under our 2019 Credit Facility and our anticipated growth and sales levels, will be sufficient to meet our anticipated cash requirement for at least the next twelve months. Our future capital requirements will depend on many factors, including, among other things, our growth rate, the timing and extent of our spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the introduction of new products.

For additional information about the 2019 Credit Facility, see Note 6 to our condensed financial statements in Part I, Item 1 of this report.

At-the-Market Sales Agreement

In August 2019, we entered into an Open Market Sale Agreement (2019 Sales Agreement) with Jefferies, LLC (Jefferies) for the offer and sale of shares of our common stock having an aggregate offering of up to $25.0 million from time to time through Jefferies, acting as our sales agent. The issuance and sale of these shares pursuant to the 2019 Sales Agreement are deemed an ATM offering under the Securities Act of 1933, as amended. Under the 2019 Sales Agreement, we agreed to pay Jefferies a commission of up to 3% of the gross proceeds of any sales made pursuant to the 2019 Sales Agreement. During the nine months ended September 30, 2020, we received net proceeds of $2.1 million after deducting commissions and expenses payable by us, from the sale of 468,427 shares of common stock pursuant to the 2019 Sales Agreement. We suspended sales under the 2019 Sales Agreement in March 2020 and terminated the ATM program in November 2020.

Cash Flows

The following table summarizes our cash flows for the periods indicated (in thousands):

	Nine Months Ended
	September 30,
	2021		2020
	(In thousands)
Cash provided by (used in) operating activities	$	2,938	$	(3,537)
Cash used in investing activities		(578)		(307)
Cash (used in) provided by financing activities		(2,401)		3,284

Cash Flows From Operating Activities

During the nine months ended September 30, 2021, cash provided by operating activities was $2.9 million, which consisted of net income of $0.7 million, cash provided by non-cash charges of $3.9 million and changes of net operating assets and liabilities of $1.6 million. The non-cash charges primarily consisted of stock-based compensation of $2.5 million, depreciation and amortization of $1.1 million, and interest expense related to the amortization of debt issuance costs of $0.3 million. The use of cash due to the change in our net operating assets and liabilities was primarily due to an increase in accounts receivable of $3.0 million due to timing of cash receipts for outstanding balances, an increase of $0.9 million in inventory due to increased inventory levels, and an increase of $0.1 million in prepaid expenses and other current assets. These uses were partially offset by an increase in deferred revenue of $1.4 million, an increase of $0.7 million in accrued liabilities due to the timing of payments, and an increase in accounts payable of $0.7 million.

During the nine months ended September 30, 2020, cash used in operating activities was $3.5 million, which consisted of a net loss of $6.9 million, adjusted by non-cash charges of $6.2 million and a change of $2.8 million in our net operating assets and liabilities. The non-cash charges primarily consisted of stock-based compensation of $2.6 million, depreciation and amortization of $1.6 million, write down of obsolete inventory of $1.7 million, and interest expense related to the amortization of debt issuance costs of $0.2 million. The use of cash due to the change in our net operating assets and liabilities was primarily due to an increase of $2.4 million in accounts receivable due to timing of cash receipts for outstanding balances and a decrease of $0.7 million in accounts payable and accrued liabilities due to the timing of payments. These changes were partially offset by a $0.4 million decrease in prepaid expenses and other current assets.

26

Cash Flows From Investing Activities

Cash used in investing activities during the nine months ended September 30, 2021 and 2020 was $0.6 million and $0.3 million, respectively, for the purchase of manufacturing and computer equipment.

Cash Flows From Financing Activities

Cash used in financing activities during the nine months ended September 30, 2021 was $2.4 million, consisting of $2.8 million of payments of term loan installments, partially offset by $0.4 million in proceeds from stock option exercises.

Cash provided by financing activities during the nine months ended September 30, 2020 was $3.3 million, consisting of $2.1 million net proceeds from the sale of our common stock in our ATM offering under our 2019 Sales Agreement with Jefferies and $1.2 million in proceeds from stock option exercises and purchase of shares in our employee stock purchase plan.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.

Critical Accounting Policies and Significant Judgements and Estimates

Our condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no changes to our critical accounting policies and estimates described in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 4, 2021, that have had a material impact on our condensed financial statements and related notes.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not required for a smaller reporting company.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures.

Our management, including our Interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO), evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of September 30, 2021, the end of the period covered by this quarterly report on Form 10-Q.

Based on this evaluation, our Interim CEO and CFO concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2021, with the exception of the ongoing material weakness discussed below.

27

Material weakness in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. In connection with the preparation of our audited annual financial statements for the year ended December 31, 2020, we determined our controls around inventory, including unit reconciliations and communication protocols between operations and accounting were not sufficiently designed to prevent and detect a material misstatement. This error was the result of a material weakness in our internal control over financial reporting, which we are in process of remediating as of September 30, 2021 through the plan outlined below.

Management’s steps taken to remediate the material weakness.

To remediate this material weakness, we have taken the following actions:

● We updated our information technology tools, including implementing a new ERP system as of January 1, 2020, to enhance our ability to monitor inventory and its movement through our manufacturing process and to provide checks and balances to third-party reports.

● We put in place management dashboard tools to alert all involved as to the performance of inventory against our business goals.

● We established multi-discipline processes to actively manage and make decisions regarding our inventory to support our business objectives.

● We provided additional training to our Operations Teams and updating procedures with our third-party Assembly Houses.

● We hired additional qualified personnel to assist management with its financial statement close process and provide oversight of our financial reporting.

We will continue to monitor stability of the platform and further enhance the business controls around inventory management. We continue to assess our accounting policies and internal controls documentation to ensure they are effective in helping us manage the business. Our management has concluded that the financial statements included elsewhere in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with GAAP.

Changes in internal control over financial reporting.

Except with respect to the remediation efforts described above, there have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent limitation on the effectiveness of internal control.

The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.

28

PART II – OTHER INFORMATION

ITEM 1. Legal Proceedings

We are not party to any material legal proceedings at this time. From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business.

ITEM 1A. Risk Factors

The following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occurs, our business, financial condition, results of operations and cash flows could be harmed. In addition, many of the following risks and uncertainties may be exacerbated by the ongoing COVID-19 pandemic, including any new variants that may become predominant, and any worsening of the global business and economic environment as a result.

Risk Factor Summary

We are subject to a variety of risks and uncertainties, including risks related to our financial condition and our indebtedness, risks related to our business and our industry, risks related to our intellectual property and technology, risks related to regulatory matters and compliance, risks related to our common stock and certain general risks, which could have a material adverse effect on our business, financial condition, results of operations and cash flows. These risks include, but are not limited to, the following principal risks:

● We may need additional funding and may be unable to raise capital when needed, which could force us to delay, reduce, or eliminate planned activities.

● ​We have a history of losses which may continue in the future, and we cannot be certain that we will achieve or sustain profitability.

● The ongoing COVID-19 global pandemic has adversely affected, and is expected to continue to adversely affect, our business, results of operations and financial condition. The widespread outbreak of any other illnesses or communicable diseases could also adversely affect our business, results of operations and financial condition.

● The limited history of STT-MRAM adoption makes it difficult to evaluate our current business and future prospects.

● We may be unable to match production with customer demand for a variety of reasons including our inability to accurately forecast customer demand or the capacity constraints of our suppliers, which could adversely affect our operating results.

● As we expand into new potential markets, we expect to face intense competition, including from our customers and potential customers, and may not be able to compete effectively, which could harm our business.

● We rely on third parties to distribute, manufacture, package, assemble and test our products, which exposes us to a number of risks, including reduced control over manufacturing and delivery timing and potential exposure to price fluctuations, which could result in a loss of revenue or reduced profitability.

● Disruptions in our supply chain may adversely impact our ability to fulfill customer demand which, in turn, may adversely impact our business, results of operations and financial condition.

● Our joint development agreement and strategic relationships involve numerous risks.

● The market for semiconductor memory products is characterized by declines in average selling prices, which we expect to continue, and which could negatively affect our revenue and margins.

● We must continuously develop new and enhanced products, and if we are unable to successfully market our new and enhanced products for which we incur significant expenses to develop, our results of operations and financial condition will be materially adversely affected.

29

● Our success and future revenue depend on our ability to secure design wins and on our customers’ ability to successfully sell the products that incorporate our solutions. Securing design wins is a lengthy, expensive, and competitive process, and may not result in actual orders and sales, which could cause our revenue to decline.

● The loss of one or several of our customers or reduced orders or pricing from existing customers may have a significant adverse effect on our operations and financial results.

● Our costs may increase substantially if we or our third-party manufacturing contractors do not achieve satisfactory product yields or quality.

● The complexity of our products may lead to defects, which could negatively impact our reputation with customers and result in liability.

● We may experience difficulties in transitioning to new wafer fabrication process technologies or in achieving higher levels of design integration, which may result in reduced manufacturing yields, delays in product deliveries and increased expenses.

● We currently maintain, and are seeking to expand, operations outside of the United States which exposes us to significant risks.

For a more complete discussion of the material risk factors applicable to us, see below.

Risk Factors Related to Our Financial Condition and Our Indebtedness

We may need additional funding and may be unable to raise capital when needed, which could force us to delay, reduce, or eliminate planned activities.

Our total revenue was approximately $36.9 million for the nine months ended September 30, 2021, and $42.0 million for the year ended December 31, 2020. As of September 30, 2021, we had cash and cash equivalents of approximately $14.6 million. Based on our current operating plan, we believe our existing cash and cash equivalents, coupled with availability under our credit facility and our anticipated growth and sales levels, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. However, our existing capital may be insufficient to meet our long-term requirements. We have no committed sources of funding other than our revolving line of credit facility and there is no assurance that additional funding will be available to us in the future or be secured on acceptable terms. If adequate funding is not available when needed, we may be forced to curtail operations, including our commercial activities and research and development programs, or cease operations altogether, file for bankruptcy, or undertake any combination of the foregoing. In such event, our stockholders may lose their entire investment in our company.

Further, we may need to raise additional funds through financings or borrowings in order to accomplish our long-term planned objectives. If we raise additional funds through issuances of equity, convertible debt securities or other securities convertible into equity, our existing stockholders could suffer significant dilution in their percentage ownership of our company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock.

In addition, if we do not meet our payment obligations to third parties as they become due, we may be subject to litigation claims and our creditworthiness would be adversely affected. Even if we are successful in defending against these claims, litigation could result in substantial costs and would be a distraction to management, and may have other unfavorable results that could further adversely impact our financial condition. Stockholders should not rely on our balance sheet as an indication of the amount of proceeds that would be available to satisfy claims of creditors, and potentially be available for distribution to stockholders, in the event of liquidation.

We have a history of losses which may continue in the future, and we cannot be certain that we will achieve or sustain profitability.

Although we generated net income of $0.9 million for the nine months ended September 30, 2021, we have historically incurred net losses since our inception. For the year ended December 31, 2020, we incurred a net loss of $8.5 million. As of September 30, 2021, we had an accumulated deficit of $156.5 million. While our products offer unique benefits over other industry memory technologies, the rate of adoption of our products and our ability to capture market share from legacy technologies is uncertain. Our revenue may also be adversely impacted by a number of other possible

30

reasons, many of which are outside our control, including business conditions that adversely affect the semiconductor memory industry resulting in a decline in end market demand for our products, adverse impacts resulting from the COVID-19 pandemic, increased competition, supply chain constraints, or our failure to capitalize on growth opportunities. We also rely on achieving specific cost reduction targets that have uncertainty in their timing and magnitude. We may also incur unforeseen expenses in the ongoing operation of our business that cause us to exceed our operational spending plan. As a result, our ability to generate sufficient revenue growth and/or controlling expenses to transition to profitability and generate consistent positive cash flows is uncertain.

Provisions of our credit facility may restrict our ability to pursue our business strategies.

Borrowings under our existing credit facility are secured by substantially all of our assets, except for intellectual property. Additionally, the operating restrictions and covenants relating to our existing credit facility restrict, and any future financing agreements that we may enter into may further restrict, our ability to finance our operations, engage in business activities or expand or fully pursue our business strategies. For example, our existing credit facility prohibits our ability to, among other things:

●    dispose of or sell assets;

●    consolidate or merge with other entities;

●    incur additional indebtedness;

●    create liens on our assets;

●    pay dividends;

●    make investments;

●    enter into transactions with affiliates; and

●    redeem subordinated indebtedness.

These restrictions are subject to certain exceptions. In addition, our existing credit facility requires that we meet certain operating covenants, such as maintaining insurance on the collateral and meeting certain financial covenants, such as maintaining a minimum cash balance and availability under our revolving line of credit facility. Our ability to comply with these covenants may be affected by events beyond our control, and we may not be able to meet those covenants. A breach of any of these covenants could result in an event of default under the credit facility. We are required to make mandatory prepayments of the outstanding loan upon the acceleration by lender following the occurrence of an event of default, along with a payment of the end of term fee, the prepayment fee and any other obligations that are due and payable at the time of prepayment. In the event of default, the interest rate in effect will increase by 5.0% per annum.

31

Risk Factors Related to Our Business and Our Industry

The ongoing COVID-19 global pandemic has adversely affected, and is expected to continue to adversely affect, our business, results of operations and financial condition. The widespread outbreak of any other illnesses or communicable diseases could also adversely affect our business, results of operations and financial condition.

We could be negatively impacted by the widespread outbreak of an illness, any other communicable disease or any other public health crisis that results in economic and trade disruptions, including the disruption of global supply chains. In late 2019, there was an outbreak of a new strain of coronavirus, COVID-19, which has since spread globally. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, “shelter-in-place,” “stay-at-home,” total lock-down orders, business limitations or shutdowns and similar orders. More recently, new variants of COVID-19, such as the Delta variant, that are significantly more contagious than previous strains have emerged. The spread of these new strains are causing many government authorities and businesses to reimplement the aforementioned measures to try to reduce the spread that had become less prevalent. The COVID-19 pandemic and its variants have negatively impacted the global economy, disrupted global supply chains and workforce participation, and initially created significant volatility and disruption of financial markets.

As a result of the COVID-19 pandemic and the related responses from government authorities, our business, results of operations and financial condition have been adversely impacted. For example, we have experienced electronics supply chain and demand disruptions from extended factory shutdowns, particularly in some Asian countries, which created unusual order patterns, and subsequently slowed Toggle MRAM demand, particularly from our industrial customers. Further, in an effort to protect the health and safety of our employees, we took the following actions: transitioned most of our office and support employees and contractors to working from home; suspended all non-essential business travel; and implemented social distancing guidelines for our employees and contractors who must work in our manufacturing and laboratory locations.

Additionally, our business, results of operations and financial condition have been and may be further impacted in several ways, including, but not limited to, the following:

● further disruptions to our operations, including due to additional facility closures, restrictions on our operations and sales, marketing and distribution efforts and/or interruptions to our research and development activities, product development and other important business activities;

● further reduced demand for our products, particularly due to disruptions to the businesses and operations of our customers;

● interruptions, availability or delays in global shipping to transport our products;

● further slowdowns, stoppages or other limitations in the supply chain for our products, in addition to higher costs, such as due to suppliers raising prices;

● limitations on employee resources and availability, including due to sickness, government restrictions, the desire of employees to avoid contact with large groups of people or mass transit disruptions;

● greater difficulty in collecting customer receivables;

● a fluctuation in foreign currency exchange rates or interest rates could result from market uncertainties; and

● an increase in the cost or the difficulty to obtain debt or equity financing could affect our financial condition or our ability to fund operations or future investment opportunities.

Additionally, COVID-19 could impact our internal controls over financial reporting as a portion of our workforce is required to work from home and therefore new processes, procedures, and controls could be required to respond to changes in our business environment. Further, should any key employees become ill from COVID-19 and unable to work, the attention of the management team could be diverted.

32

The emergence of the significantly more contagious Delta variant of COVID-19 and the prevalence of breakthrough cases of infection among fully vaccinated people adds additional uncertainty and could result in further impacts to our business and operations, including those discussed above.

Although we will continue to monitor the situation and take further actions, which may include further altering our operations, in order to protect the best interests of our employees, customers and suppliers and comply with government requirements, there is no certainty that such measures will be enough to mitigate the risks posed by the virus, and our ability to perform critical functions could be harmed.

Any of the foregoing could adversely affect our business, results of operations and financial condition. The potential effects of COVID-19 may also impact many of our other risk factors discussed in this “Risk Factors” section. The ultimate extent of the impact of the COVID-19 pandemic on our business, results of operations and financial condition will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted, including, but not limited to, the duration and spread of the COVID-19 outbreak and its severity; the emergence and severity of its variants, including the Delta variant; the actions to contain the virus or treat its impact, such as the availability and efficacy of vaccines (particularly with respect to emerging strains of the virus) and potential hesitancy to utilize them; general economic factors, such as increased inflation; supply chain restraints; labor supply issues; and how quickly and to what extent normal economic and operating conditions can resume.

The limited history of STT-MRAM adoption makes it difficult to evaluate our current business and future prospects.

We have been in existence as a stand-alone company since 2008, when Freescale Semiconductor, Inc. (subsequently acquired by NXP Semiconductor) spun-out its MRAM business as Everspin. We have been shipping magnetoresistive random-access memory (MRAM) products since our incorporation in 2008. However, we only began to manufacture and ship our Spin Transfer Torque MRAM (STT-MRAM) products in the fourth quarter of 2017.

Our limited experience selling our STT-MRAM products, combined with the rapidly evolving and competitive nature of our market, makes it difficult to evaluate our current business and future prospects. In addition, we have limited insight into emerging trends that may adversely affect our business, financial condition, results of operations and prospects. We have encountered and will continue to encounter risks and difficulties frequently experienced by growing companies in rapidly changing industries, including unpredictable and volatile revenue and increased expenses as we continue to grow our business. The viability and demand for our products may be affected by many factors outside of our control, such as the factors affecting the growth of the industrial, automotive, transportation, and data center market segments and changes in macroeconomic conditions. If we do not manage these risks and overcome these difficulties successfully, our business will suffer.

We may be unable to match production with customer demand for a variety of reasons including our inability to accurately forecast customer demand, supply chain constraints, or the capacity constraints of our suppliers, which could adversely affect our operating results.

We make planning and spending decisions, including determining production levels, production schedules, component procurement commitments, personnel needs and other resource requirements, based on our estimates of product demand and customer requirements. Our products are typically purchased pursuant to individual purchase orders. While our customers may provide us with their demand forecasts, they are not contractually committed to buy any quantity of products beyond purchase orders. Furthermore, many of our customers may increase, decrease, cancel or delay purchase orders already in place without significant penalty. The short-term nature of commitments by our customers and the possibility of unexpected changes in demand for their products reduce our ability to accurately estimate future customer requirements. On occasion, customers may require rapid increases in production, which can strain our resources, necessitate more onerous procurement commitments and reduce our gross margin. If we overestimate customer demand, we may purchase products that we may not be able to sell, which could result in decreases in our prices or write-downs of unsold inventory. Conversely, we could lose sales opportunities and could lose market share or damage our customer relationships if, for example, we underestimate customer demand, are affected by supply chain constraints, or sufficient manufacturing is unavailable. We manufacture MRAM products at our 200mm facility we lease in Chandler, Arizona and use a single foundry, GLOBALFOUNDRIES, for production of higher density products on advanced technology nodes, which may not have sufficient capacity to meet customer demand. The rapid pace of innovation in our industry could also render significant portions of our inventory obsolete. Excess or

33

obsolete inventory levels could result in unexpected expenses or write-downs of inventory values that could adversely affect our business, operating results and financial condition.

As we expand into new potential markets, we expect to face intense competition, including from our customers and potential customers, and may not be able to compete effectively, which could harm our business.

We expect that our new and future MRAM products will be applicable to markets in which we are not currently operating. The markets in which we operate and may operate in the future are extremely competitive and are characterized by rapid technological change, continuous evolving customer requirements and declining average selling prices. We may not be able to compete successfully against current or potential competitors, which include our current or potential customers as they seek to internally develop solutions competitive with ours or as we develop products potentially competitive with their existing products. If we do not compete successfully, our market share and revenue may decline. We compete with large semiconductor manufacturers and designers and others, and our current and potential competitors have longer operating histories, significantly greater resources and name recognition and a larger base of customers than we do. This may allow them to respond more quickly than we can to new or emerging technologies or changes in customer requirements. In addition, these competitors may have greater credibility with our existing and potential customers. Some of our current and potential customers with their own internally developed solutions may choose not to purchase products from third-party suppliers like us.

We rely on third parties to distribute, manufacture, package, assemble and test our products, which exposes us to a number of risks, including reduced control over manufacturing and delivery timing and potential exposure to price fluctuations, which could result in a loss of revenue or reduced profitability.

Although we operate an integrated magnetic fabrication line located in Chandler, Arizona, we purchase wafers from third parties and outsource the manufacturing, packaging, assembly and testing of our products to third-party foundries and assembly and testing service providers. We use a single foundry, GLOBALFOUNDRIES Singapore Pte. Ltd., for production of higher density products on advanced technology nodes. Our primary product package and test operations are located in China, Taiwan and other Asian countries. We also use standard CMOS wafers from third-party foundries, which we process at our Chandler, Arizona facility.

Relying on third-party distribution, manufacturing, assembly, packaging and testing presents a number of risks, including but not limited to:

●    our interests could diverge from those of our foundries, or we may not be able to agree with them on ongoing development, manufacturing and operational activities, or on the amount, timing, or nature of further investments in our joint development;

●    capacity and materials shortages during periods of high demand or supply constraints;

●    reduced control over delivery schedules, inventories and quality;

●    the unavailability of, or potential delays in obtaining access to, key process technologies;

●    the inability to achieve required production or test capacity and acceptable yields on a timely basis;

●    misappropriation of our intellectual property;

●    the third party’s ability to perform its obligations due to bankruptcy or other financial constraints;

●    exclusive representatives for certain customer engagements;

●    limited warranties on wafers or products supplied to us; and

●    potential increases in prices including due to inflation.

Our manufacturing agreement with GLOBALFOUNDRIES includes a customary forecast and ordering mechanism for the supply of certain of our wafers, and we are obligated to order and pay for, and GLOBALFOUNDRIES is

34

obligated to supply, wafers consistent with the binding portion of our forecast. However, our manufacturing arrangement is also subject to both a minimum and maximum order quantity that while we believe currently addresses our projected foundry capacity needs, may not address our maximum foundry capacity requirements in the future. We may also be obligated to pay for unused capacity if our demand decreases in the future, or if our estimates prove inaccurate. GLOBALFOUNDRIES also has the ability to discontinue its manufacture of any of our wafers upon due notice and completion of the notice period. This could cause us to have to find another foundry to manufacture those wafers or redesign our core technology and would mean that we may not have products to sell until such time. Any time spent engaging a new manufacturer or redesigning our core technology could be costly and time consuming and may allow potential competitors to take opportunities in the marketplace. Moreover, if we are unable to find another foundry to manufacture our products or if we have to redesign our core technology, this could cause material harm to our business and operating results.

If we need other foundries or packaging, assembly and testing contractors, or if we are unable to obtain timely and adequate deliveries from our providers, we might not be able to cost-effectively and quickly retain other vendors to satisfy our requirements. Because the lead time needed to establish a relationship with a new third-party supplier could be several quarters, there is no readily available alternative source of supply for any specific component. In addition, the time and expense to qualify a new foundry could result in additional expense, diversion of resources or lost sales, any of which would negatively impact our financial results.

If any of our current or future foundries or packaging, assembly and testing subcontractors significantly increases the costs of wafers or other materials or services, interrupts or reduces our supply, including for reasons outside of their control, such as due to the COVID-19 pandemic, or if any of our relationships with our suppliers is terminated, our operating results could be adversely affected. Such occurrences could also damage our customer relationships, result in lost revenue, cause a loss in market share or damage our reputation.

Disruptions in our supply chain may adversely impact our ability to fulfill customer demand which, in turn, may adversely impact our business, results of operations and financial condition.

If we fail to procure sufficient components used in our products, we may be unable to deliver our products to our customers on a timely basis, which could lead to customer dissatisfaction and could harm our reputation and ability to compete. We would likely experience significant delays or cessation in producing some of our products if a labor strike, natural disaster, public health crisis or other supply disruption were to occur, including as a result of the COVID-19 pandemic, at any of our main suppliers.

In particular, the post-COVID-19 upturn in the semiconductor industry has stretched the supply chain, and we are subject to supply shortages, as well as higher costs as suppliers opportunistically raise prices. For example, there is currently a worldwide shortage of semiconductor, memory and other electronic components affecting many industries. Our products are dependent on some of these electronic components. A continued shortage of electronic components may impact us significantly and could cause us to experience extended lead times and increased prices from our suppliers, which could be significant. Extended lead times and decreased availability of key components could result in a significant disruption to our production schedule, all of which would have an adverse effect on our business, results of operations and financial condition. We do not have any guarantees of supply from our third-party suppliers, and in certain cases we have limited contractual arrangements or are relying on standard purchase orders or on component parts available on the open market, which may further result in increased costs combined with reduced availability. A continued delay in our ability to produce and deliver our products could also cause our customers to purchase alternative products from our competitors and/or harm our reputation. 

Our joint development agreement and strategic relationships involve numerous risks.

We have entered into strategic relationships to manufacture products and develop new manufacturing process technologies and products. These relationships include our joint development agreement with GLOBALFOUNDRIES to develop advanced MTJ technology and STT-MRAM. These relationships are subject to various risks that could adversely affect the value of our investments and our results of operations. These risks include the following:

●    our interests could diverge from those of our foundries, or we may not be able to agree with them on ongoing development, manufacturing and operational activities, or on the amount, timing, or nature of further investments in our joint development;

35

●    we may experience difficulties in transferring technology to a foundry;

●    we may experience difficulties and delays in getting to and/or ramping production at foundries;

●    our control over the operations of foundries is limited;

●    due to financial constraints, our joint development collaborators may be unable to meet their commitments to us and may pose credit risks for our transactions with them;

●    due to differing business models or long-term business goals, our collaborators may decide not to join us in funding capital investment, which may result in higher levels of cash expenditures by us;

●    our cash flows may be inadequate to fund increased capital requirements;

●    we may experience difficulties or delays in collecting amounts due to us from our collaborators;

●    the terms of our arrangements may turn out to be unfavorable;

●    we are migrating toward a fabless model as 300mm production becomes required and this increases risks related to less control over our critical production processes; and

●    changes in tax, legal, or regulatory requirements may necessitate changes in our agreements.

The term of the agreement, as amended, is the completion, termination, or expiration of the last statement of work

entered into pursuant to the joint development agreement.

If our strategic relationships are unsuccessful, our business, results of operations, or financial condition may be materially adversely affected.

The market for semiconductor memory products is characterized by declines in average selling prices, which we expect to continue, and which could negatively affect our revenue and margins.

Our customers for some of our products may see the average selling price of competitive products decrease year-over-year and we expect this trend to continue. When such pricing declines occur, we may not be able to mitigate the effects by selling more or higher margin units, or by reducing our manufacturing costs. In such circumstances, our operating results could be materially and adversely affected. Our stand-alone and embedded MRAM products have experienced declining average selling prices over their life cycle. The rate of decline may be affected by a number of factors, including relative supply and demand, the level of competition, production costs and technological changes. As a result of the decreasing average selling prices of our products following their launch, our ability to increase or maintain our margins depends on our ability to introduce new or enhanced products with higher average selling prices and to reduce our per-unit cost of sales and our operating costs. We may not be able to reduce our costs as rapidly as companies that operate their own manufacturing, assembly and testing facilities, and our costs may even increase because we rely in part on third parties to manufacture, assemble and test our products, which could also reduce our gross margins. In addition, our new or enhanced products may not be as successful or enjoy as high margins as we expect. If we are unable to offset any reductions in average selling prices by introducing new products with higher average selling prices or reducing our costs, our revenue and margins will be negatively affected and may decrease.

The semiconductor memory market is highly cyclical and has experienced severe downturns in the past, generally as a result of wide fluctuations in supply and demand, constant and rapid technological change, continuous new product introductions and price erosion. During downturns, periods of intense competition, or the presence of oversupply in the industry, the selling prices for our products may decline at a high rate over relatively short time periods as compared to historical rates of decline. We are unable to predict selling prices for any future periods and may experience unanticipated, sharp declines in selling prices for our products.

36

We must continuously develop new and enhanced products, and if we are unable to successfully market our new and enhanced products for which we incur significant expenses to develop, our results of operations and financial condition will be materially adversely affected.

To compete effectively in our markets, we must continually design, develop and introduce new and improved technology and products with improved features in a cost-effective manner in response to changing technologies and market demand. This requires us to devote substantial financial and other resources to research and development. We are developing new technology and products, which we expect to be one of the drivers of our revenue growth in the future. We also face the risk that customers may not value or be willing to bear the cost of incorporating our new and enhanced products into their products, particularly if they believe their customers are satisfied with current solutions. Regardless of the improved features or superior performance of our new and enhanced products, customers may be unwilling to adopt our solutions due to design or pricing constraints, or because they do not want to rely on a single or limited supply source. Because of the extensive time and resources that we invest in developing new and enhanced products, if we are unable to sell customers our new products, our revenue could decline and our business, financial condition, results of operations and cash flows would be negatively affected. For example, if we are unable to generate more customer adoption of our 1Gb product and address new growth opportunities with subsequent STT-MRAM products, we may not be able to materially increase our revenue. If we are unable to successfully develop and market our new and enhanced products that we have incurred significant expenses developing, our results of operations and financial condition will be materially and adversely affected.

Our success and future revenue depend on our ability to secure design wins and on our customers’ ability to successfully sell the products that incorporate our solutions. Securing design wins is a lengthy, expensive and competitive process, and may not result in actual orders and sales, which could cause our revenue to decline.

We sell to customers, including OEMs and ODMs, that incorporate MRAM into their products. A design win occurs after a customer has tested our product, verified that it meets the customer’s requirements and qualified our solutions for their products. We believe we are dependent, among other things, on the adoption of our 256Mb and 1Gb MRAM products by our customers to secure design wins. Our customers may need several months to years to test, evaluate and adopt our product and additional time to begin volume production of the product that incorporates our solution. Due to this generally lengthy design cycle, we may experience significant delays from the time we increase our operating expenses and make investments in our products to the time that we generate revenue from sales of these products. Moreover, even if a customer selects our solution, we cannot guarantee that this will result in any sales of our products, as the customer may ultimately change or cancel its product plans, or efforts by our customer to market and sell its product may not be successful. We may not generate any revenue from design wins after incurring the associated costs, which would cause our business and operating results to suffer.

If a current or prospective customer incorporates a competitor’s solution into its product, it becomes significantly more difficult for us to sell our solutions to that customer because changing suppliers involves significant time, cost, effort and risk for the customer even if our solutions are superior to other solutions and remain compatible with their product design. Our ability to compete successfully depends on customers viewing us as a stable and reliable supplier to mission-critical customer applications when we have less production capacity and less financial resources compared to most of our larger competitors. If current or prospective customers do not include our solutions in their products and we fail to achieve a sufficient number of design wins, our results of operations and business may be harmed.

The loss of one or several of our customers or reduced orders or pricing from existing customers may have a significant adverse effect on our operations and financial results.

We have derived and expect to continue to derive a significant portion of our revenues from a small group of customers during any particular period due in part to the concentration of market share in the semiconductor industry. Our four largest end customers together accounted for 44% of our total revenue for the nine months ended September 30, 2021, and one of these customers accounted for more than 10% of our revenue during that period. Our four largest end customers together accounted for 45% of our total revenue for the year ended December 31, 2020, and one of these customers individually accounted for more than 10% of our total revenue during the period. The loss of a significant customer, a business combination among our customers, a reduction in orders or decrease in price from a significant customer or disruption in any of our commercial or distributor arrangements may result in a significant decline in our revenues and could have a material adverse effect on our business, liquidity, results of operations, financial condition and cash flows.

37

We face competition and expect competition to increase in the future. If we fail to compete effectively, our revenue growth and results of operations will be materially and adversely affected.

The global semiconductor market in general, and the semiconductor memory market in particular, are highly competitive. We expect competition to increase and intensify as other semiconductor companies enter our markets, many of which have greater financial and other resources with which to pursue technology development, product design, manufacturing, marketing and sales and distribution of their products. Increased competition could result in price pressure, reduced profitability and loss of market share, any of which could materially and adversely affect our business, revenue and operating results. Currently, our competitors range from large, international companies offering a wide range of traditional memory technologies to companies specializing in other alternative, specialized emerging memory technologies. Our primary memory competitors include Fujitsu, Infineon, Integrated Silicon Solution, Intel, Macronix, Microchip, Micron, Renesas, Samsung, and Toshiba. In addition, as the MRAM market opportunity grows, we expect new entrants may enter this market and existing competitors, including leading semiconductor companies, may make significant investments to compete more effectively against our products. These competitors could develop technologies or architectures that make our products or technologies obsolete.

Our ability to compete successfully depends on factors both within and outside of our control, including:

●    the functionality and performance of our products and those of our competitors;

●    our relationships with our customers and other industry participants;

●    prices of our products and prices of our competitors’ products;

●    our ability to develop innovative products;

●    our competitors’ greater resources to make acquisitions;

●    our ability to obtain adequate capital to finance operations;

●    our ability to retain high-level talent, including our management team and engineers; and

●    the actions of our competitors, including merger and acquisition activity, launches of new products and other actions that could change the competitive landscape.

Competition could result in pricing pressure, reduced revenue and loss of market share, any of which could materially and adversely affect our business, results of operations and prospects. In the event of a market downturn, competition in the markets in which we operate may intensify as our customers reduce their purchase orders. Our competitors that are significantly larger and have greater financial, technical, marketing, distribution, customer support and other resources or more established market recognition than us may be better positioned to accept lower prices and withstand adverse economic or market conditions.

Our costs may increase substantially if we or our third-party manufacturing contractors do not achieve satisfactory product yields or quality.

The fabrication process is extremely complicated and small changes in design, specifications or materials can result in material decreases in product yields or even the suspension of production. From time to time, we and/or the third-party foundries that we contract to manufacture our products may experience manufacturing defects and reduced manufacturing yields. In some cases, we and/or our third-party foundries may not be able to detect these defects early in the fabrication process or determine the cause of such defects in a timely manner. There may be a higher risk of product yield issues in newer STT-MRAM products.

Generally, in pricing our products, we assume that manufacturing yields will continue to improve, even as the complexity of our products increases. Once our products are initially qualified either internally or with our third-party foundries, minimum acceptable yields are established. We are responsible for the costs of the units if the actual yield is above the minimum set with our third-party foundries. If actual yields are below the minimum, we are not required to

38

purchase the units. Typically, minimum acceptable yields for our new products are generally lower at first and gradually improve as we achieve full production, but yield issues can occur even in mature processes due to break downs in mechanical systems, equipment failures or calibration errors. Unacceptably low product yields or other product manufacturing problems could substantially increase overall production time and costs and adversely impact our operating results. Product yield losses may also increase our costs and reduce our gross margin. In addition to significantly harming our results of operations and cash flow, poor yields may delay shipment of our products and harm our relationships with existing and potential customers.

The complexity of our products may lead to defects, which could negatively impact our reputation with customers and result in liability.

Products as complex as ours may contain defects when first introduced to customers or as new versions are released. Delivery of products with production defects or reliability, quality or compatibility problems could significantly delay or hinder market acceptance of the products or result in a costly recall and could damage our reputation and adversely affect our ability to retain existing customers and attract new customers. Defects could cause problems with the functionality of our products, resulting in interruptions, delays or cessation of sales of these products to our customers. We may also be required to make significant expenditures of capital and resources to resolve such problems. We cannot assure our stockholders that problems will not be found in new products, both before and after commencement of commercial production, despite testing by us, our suppliers or our customers. Any such problems could result in:

●    delays in development, manufacture and roll-out of new products;

●    additional development costs;

●    loss of, or delays in, market acceptance;

●    diversion of technical and other resources from our other development efforts;

●    claims for damages by our customers or others against us; and

●    loss of credibility with our current and prospective customers.

Any such event could have a material adverse effect on our business, financial condition and results of operations.

We may experience difficulties in transitioning to new wafer fabrication process technologies or in achieving higher levels of design integration, which may result in reduced manufacturing yields, delays in product deliveries and increased expenses.

We aim to use the most advanced manufacturing process technology appropriate for our solutions that is available from our third-party foundries. As a result, we periodically evaluate the benefits of migrating our solutions to other technologies to improve performance and reduce costs. These ongoing efforts require us from time to time to modify the manufacturing processes for our products and to redesign some products, which in turn may result in delays in product deliveries.

For example, as smaller line width geometry manufacturing processes become more prevalent, we intend to move our future products to increasingly smaller geometries to integrate greater levels of memory capacity and/or functionality into our products. This transition will require us and our third-party foundries to migrate to new designs and manufacturing processes for smaller geometry products.

We may face difficulties, delays and increased expense as we transition our products to new processes, and potentially to new foundries. We will depend on our third-party foundries as we transition to new processes. We cannot assure our stockholders that our third-party foundries will be able to effectively manage such transitions or that we will be able to maintain our relationship with our third-party foundries or develop relationships with new third-party foundries. If we or any of our third-party foundries experience significant delays in transitioning to new processes or fail to efficiently implement transitions, we could experience reduced manufacturing yields, delays in product deliveries and increased expenses, any of which could harm our relationships with our customers and our operating results.

39

Changes to industry standards and technical requirements relevant to our products and markets could adversely affect our business, results of operations and prospects.

Our products are only a part of larger electronic systems. All products incorporated into these systems must comply with various industry standards and technical requirements created by regulatory bodies or industry participants to operate efficiently together. Industry standards and technical requirements in our markets are evolving and may change significantly over time. For our products, the industry standards are developed by the Joint Electron Device Engineering Council, an industry trade organization. In addition, large industry-leading semiconductor and electronics companies play a significant role in developing standards and technical requirements for the product ecosystems within which our products can be used. Our customers also may design certain specifications and other technical requirements specific to their products and solutions. These technical requirements may change as the customer introduces new or enhanced products and solutions.

Our ability to compete in the future will depend on our ability to identify and comply with evolving industry standards and technical requirements. The emergence of new industry standards and technical requirements could render our products incompatible with products developed by other suppliers or make it difficult for our products to meet the requirements of certain of our customers in automotive, transportation, industrial, storage and other markets. As a result, we could be required to invest significant time and effort and to incur significant expense to redesign our products to ensure compliance with relevant standards and requirements. If our products are not in compliance with prevailing industry standards and technical requirements for a significant period of time, we could miss opportunities to achieve crucial design wins, our revenue may decline and we may incur significant expenses to redesign our products to meet the relevant standards, which could adversely affect our business, results of operations and prospects.

Our success depends on our ability to attract and retain key employees, and our failure to do so could harm our ability to grow our business and execute our business strategies.

Our success depends on our ability to attract and retain our key employees, including our management team and experienced engineers. Competition for personnel in the semiconductor memory technology field, and in the MRAM space in particular, is intense, and the availability of suitable and qualified candidates is limited. We compete to attract and retain qualified research and development personnel with other semiconductor companies, universities and research institutions. Given our experience as an early entrant in the MRAM space, our employees are frequently contacted by MRAM startups and MRAM groups within larger companies seeking to employ them. The members of our management and our key employees are at-will. If we lose the services of any key senior management member or employee, we may not be able to locate suitable or qualified replacements, and may incur additional expenses to recruit and train new personnel, which could severely impact our business and prospects. The loss of the services of one or more of our key employees, especially our key engineers, or our inability to attract and retain qualified engineers, could harm our business, financial condition and results of operations.

We currently maintain, and are seeking to expand, operations outside of the United States which exposes us to significant risks.

The success of our business depends, in large part, on our ability to operate successfully from geographically disparate locations and to further expand our international operations and sales. Operating in international markets requires significant resources and management attention and subjects us to regulatory, economic and political risks that are different from those we face in the United States. We cannot be sure that further international expansion will be successful. In addition, we face risks in doing business internationally that could expose us to reduced demand for our products, lower prices for our products or other adverse effects on our operating results. Among the risks we believe are most likely to affect us are:

● public health issues, such as the COVID-19 pandemic, which can result in varying impacts to our business, employees, partners, customers, distributors or suppliers internationally as discussed elsewhere in this “Risk Factors” section;

● difficulties, inefficiencies and costs associated with staffing and managing foreign operations;

● longer and more difficult customer qualification and credit checks;

40

● greater difficulty collecting accounts receivable and longer payment cycles;

● the need for various local approvals to operate in some countries;

● difficulties in entering some foreign markets without larger-scale local operations;

● changes in import/export laws, trade restrictions, regulations and customs and duties and tariffs (foreign and domestic);

● compliance with local laws and regulations;

● unexpected changes in regulatory requirements, including the elimination of tax holidays;

● reduced protection for intellectual property rights in some countries;

● adverse tax consequences as a result of repatriating cash generated from foreign operations to the United States;

● adverse tax consequences, including potential additional tax exposure if we are deemed to have established a permanent establishment outside of the United States;

● the effectiveness of our policies and procedures designed to ensure compliance with the Foreign Corrupt Practices Act of 1977 and similar regulations;

● fluctuations in currency exchange rates, which could increase the prices of our products to customers outside of the United States, increase the expenses of our international operations by reducing the purchasing power of the U.S. dollar and expose us to foreign currency exchange rate risk if, in the future, we denominate our international sales in currencies other than the U.S. dollar;

● new and different sources of competition; and

● political and economic instability, and terrorism.

Our failure to manage any of these risks successfully could harm our operations and reduce our revenue.

We may not successfully manage the transitions associated with certain of our executive officers, which could have an adverse impact on us.

In December 2020, Kevin Conley notified our board of directors of his decision to resign as President and Chief Executive Officer of the Company. In connection with Mr. Conley’s resignation, our board of directors appointed Darin Billerbeck to serve as Interim Chief Executive Officer of the Company until a permanent successor can be named. Our board of directors intends to initiate a search process to select the Company’s next Chief Executive Officer.

Although our board of directors is confident in the interim leadership of Mr. Billerbeck, leadership transitions can be inherently difficult to manage. An inadequate transition to a permanent Chief Executive Officer or with respect to other executive officer transitions, including the appointment of Anuj Aggarwal as the Company’s permanent Chief Financial Officer in September 2021 may cause disruption within the Company. In addition, if we are unable to attract and retain a qualified candidate to become the permanent Chief Executive Officer or in a timely manner, our financial performance and ability to meet operational goals and strategic plans may be adversely impacted. This may also impact our ability to retain and hire other key members of management.

Risk Factors Related to Our Intellectual Property and Technology
​

Failure to protect our intellectual property could substantially harm our business.

Our success and ability to compete depend in part upon our ability to protect our intellectual property. We rely on a combination of intellectual property rights, including patents, mask work protection, copyrights, trademarks, trade secrets and know-how, in the United States and other jurisdictions. The steps we take to protect our intellectual property

41

rights may not be adequate, particularly in foreign jurisdictions such as China. Any patents we hold may not adequately protect our intellectual property rights or our products against competitors, and third parties may challenge the scope, validity or enforceability of our issued patents, which third parties may have significantly more financial resources with which to litigate their claims than we have to defend against them. In addition, other parties may independently develop similar or competing technologies designed around any patents or patent applications that we hold. Some of our products and technologies are not covered by any patent or patent application, as we do not believe patent protection of these products and technologies is critical to our business strategy at this time. A failure to timely seek patent protection on products or technologies generally precludes us from seeking future patent protection on these products or technologies.

In addition to patents, we also rely on contractual protections with our customers, suppliers, distributors, employees and consultants, and we implement security measures designed to protect our trade secrets and know-how. However, we cannot assure our stockholders that these contractual protections and security measures will not be breached, that we will have adequate remedies for any such breach or that our customers, suppliers, distributors, employees or consultants will not assert rights to intellectual property or damages arising out of such contracts.

We may initiate claims against third parties to protect our intellectual property rights if we are unable to resolve matters satisfactorily through negotiation. Litigation brought to protect and enforce our intellectual property rights could be costly, time-consuming and distracting to management. It could also result in the impairment or loss of portions of our intellectual property, as an adverse decision could limit our ability to assert our intellectual property rights, limit the value of our technology or otherwise negatively impact our business, financial condition and results of operations. Additionally, any enforcement of our patents or other intellectual property may provoke third parties to assert counterclaims against us. Our failure to secure, protect and enforce our intellectual property rights could materially harm our business.

We may face claims of intellectual property infringement, which could be time-consuming, costly to defend or settle, result in the loss of significant rights, harm our relationships with our customers and distributors, or otherwise materially adversely affect our business, financial condition and results of operations.

The semiconductor memory industry is characterized by companies that hold patents and other intellectual property rights and that vigorously pursue, protect and enforce intellectual property rights. These companies include patent holding companies or other adverse patent owners who have no relevant product revenue and against whom our own patents may provide little or no deterrence. From time to time, third parties may assert against us and our customers’ patent and other intellectual property rights to technologies that are important to our business. We have in the past, and may in the future, face such claims.

Claims that our products, processes or technology infringe third-party intellectual property rights, regardless of their merit or resolution, could be costly to defend or settle and could divert the efforts and attention of our management and technical personnel. We may also be obligated to indemnify our customers or business partners in connection with any such litigation, which could result in increased costs. Infringement claims also could harm our relationships with our customers or distributors and might deter future customers from doing business with us. If any such proceedings result in an adverse outcome, we could be required to:

●    cease the manufacture, use or sale of the infringing products, processes or technology;

●    pay substantial damages for infringement;

●    expend significant resources to develop non-infringing products, processes or technology, which may not be successful;

●    license technology from the third-party claiming infringement, which license may not be available on commercially reasonable terms, or at all;

●    cross-license our technology to a competitor to resolve an infringement claim, which could weaken our ability to compete with that competitor; or

●    pay substantial damages to our customers to discontinue their use of or to replace infringing technology sold to them with non-infringing technology, if available.

42

Any of the foregoing results could have a material adverse effect on our business, financial condition and results of operations. Furthermore, our exposure to the foregoing risks may also be increased if we acquire other companies or technologies. For example, we may have a lower level of visibility into the development process with respect to intellectual property or the care taken to safeguard against infringement risks with respect to the acquired company or technology. In addition, third parties may make infringement and similar or related claims after we have acquired technology that had not been asserted prior to the acquisition.

We make significant investments in new technologies and products that may not achieve technological feasibility or profitability or that may limit our revenue growth.

We have made and will continue to make significant investments in research and development of new technologies and products, including new and more technically advanced versions of our MRAM technology.

Investments in new technologies are speculative and technological feasibility may not be achieved. Commercial success depends on many factors including demand for innovative technology, availability of materials and equipment, selling price the market is willing to bear, competition and effective licensing or product sales. We may not achieve significant revenue from new product investments for a number of years, if at all. Moreover, new technologies and products may not be profitable, and even if they are profitable, operating margins for new products and businesses may not be as high as the margins we have experienced historically or originally anticipated. Our inability to capitalize on or realize substantial revenue from our significant investments in research and development could harm our operating results and distract management, harming our business.

Interruptions in our information technology systems could adversely affect our business.

We rely on the efficient and uninterrupted operation of complex information technology systems and networks to operate our business. Any significant disruption to our systems or networks, including, but not limited to, new system implementations, computer viruses, security breaches, facility issues, natural disasters, terrorism, war, telecommunication failures or energy blackouts, could have a material adverse impact on our operations, sales and financial results. Such disruption could result in a loss of our intellectual property or the release of sensitive competitive information or supplier, customer or employee personal data. Any loss of such information could harm our competitive position, result in a loss of customer confidence, and cause us to incur significant costs to remedy the damages caused by any such disruptions or security breaches. Additionally, any failure to properly manage the collection, handling, transfer or disposal of personal data of employees and customers may result in regulatory penalties, enforcement actions, remediation obligations, litigation, fines and other sanctions.

We may experience attacks on our data, attempts to breach our security and attempts to introduce malicious software into our IT systems. If attacks are successful, we may be unaware of the incident, its magnitude, or its effects until significant harm is done. Any such attack or disruption could result in additional costs related to rebuilding of our internal systems, defending litigation, responding to regulatory actions, or paying damages. Such attacks or disruptions could have a material adverse impact on our business, operations and financial results.

Third-party service providers, such as wafer foundries, assembly and test contractors, distributors and other vendors have access to certain portions of our and our customers’ sensitive data. In the event that these service providers do not properly safeguard the data that they hold, security breaches and loss of data could result. Any such loss of data by our third-party service providers could negatively impact our business, operations and financial results, as well as our relationship with our customers.

Risk Factors Related to Regulatory Matters and Compliance

To comply with environmental laws and regulations, we may need to modify our activities or incur substantial costs, and if we fail to comply with environmental regulations, we could be subject to substantial fines or be required to have our suppliers alter their processes.

The semiconductor memory industry is subject to a variety of international, federal, state and local governmental regulations directed at preventing or mitigating environmental harm, as well as to the storage, discharge, handling, generation, disposal and labeling of toxic or other hazardous substances. Failure to comply with environmental

43

regulations could subject us to civil or criminal sanctions and property damage or personal injury claims. Compliance with current or future environmental laws and regulations could restrict our ability to expand our business or require us to modify processes or incur other substantial expenses which could harm our business. In response to environmental concerns, some customers and government agencies impose requirements for the elimination of hazardous substances, such as lead (which is widely used in soldering connections in the process of semiconductor packaging and assembly), from electronic equipment. For example, the European Union adopted its Restriction on Hazardous Substance Directive which prohibits, with specified exceptions, the sale in the EU market of new electrical and electronic equipment containing more than agreed levels of lead or other hazardous materials and China has enacted similar regulations. Environmental laws and regulations such as these could become more stringent over time, causing a need to redesign technologies, imposing greater compliance costs and increasing risks and penalties associated with violations, which could seriously harm our business.

Increasing public attention has been focused on the environmental impact of electronic manufacturing operations. While we have not experienced any materially adverse effects on our operations from recently adopted environmental regulations, our business and results of operations could suffer if for any reason we fail to control the storage or use of, or to adequately restrict the discharge or disposal of, hazardous substances under present or future environmental regulations.

Regulations related to “conflict minerals” may force us to incur additional expenses, may make our supply chain more complex and may result in damage to our reputation with customers.

Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC has adopted requirements for companies that use certain minerals and metals, known as conflict minerals, in their products, whether or not these products are manufactured by third parties. These requirements require companies to perform diligence and disclose and report whether or not such minerals originate from the Democratic Republic of Congo and adjoining countries. These requirements could adversely affect the sourcing, availability and pricing of minerals used in the manufacture of our products, and affect our costs and relationships with customers, distributors and suppliers as we must obtain additional information from them to ensure our compliance with the disclosure requirement. In addition, we incur additional costs in complying with the disclosure requirements, including costs related to determining the source of any of the relevant minerals and metals used in our products. Since our supply chain is complex, we have not been able to sufficiently verify the origins for these minerals and metals used in our products through the due diligence procedures that we implement, which may harm our reputation. In such event, we may also face difficulties in satisfying customers who require that all of the components of our products are certified as conflict mineral free and these customers may discontinue, or materially reduce, purchases of our products, which could result in a material adverse effect on our results of operations and our financial condition may be adversely affected.

Our ability to use net operating losses to offset future taxable income may be subject to certain limitations.

In general, under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating losses, or NOLs, to offset future taxable income and tax credits to offset tax. As of December 31, 2020, we had gross federal net operating loss carryforwards of approximately $140.5 million, of which $99.7 million will expire in 2028 through 2037 if not utilized, and $40.8 million will carryover indefinitely. As of December 31, 2020, we had state net operating loss carryforwards of approximately $54.1 million, of which $51.5 million will expire in 2023 through 2040 if not utilized, and $2.6 million will carryover indefinitely. The federal NOLs generated prior to 2018 will continue to be governed by the NOL tax rules as they existed prior to the adoption of the 2017 Tax Cuts and Jobs Act (2017 Tax Act), which means that generally they will expire 20 years after they were generated if not used prior thereto. The 2017 Tax Act repealed the 20-year carryforward and two-year carryback of NOLs originating after December 31, 2017 and also limits the NOL deduction to 80% of taxable income for tax years beginning after December 31, 2017. Any NOLs generated in 2018 and forward will be carried forward and will not expire. There is no current impact to us as we continue to be in a loss position for U.S. income tax purposes. Future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Section 382 of the Code. The ability to utilize our net operating losses and tax credits could also be impaired under state law. As a result, we might not be able to utilize a material portion of our state NOLs and tax credits.

44

Risks Related to Our Common Stock

We expect that the price of our common stock will fluctuate substantially.

The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:

●    the duration and severity of the COVID-19 pandemic and its effects on our business, financial condition, results of operations and cash flows;

●    the introduction of new products or product enhancements by us or others in our industry;

●    announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or restructurings;

●    disputes or other developments with respect to our or others’ intellectual property rights;

●    product liability claims or other litigation;

●    quarterly variations in our results of operations or those of others in our industry;

●    sales of large blocks of our common stock, including sales by our executive officers and directors;

●    changes in senior management or key personnel;

●    changes in earnings estimates or recommendations by securities analysts; and

●    general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, including those due to the duration and severity of the COVID-19 pandemic.

Stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Further, the semiconductor memory industry is highly cyclical and our markets may experience significant cyclical fluctuations in demand as a result of changing economic conditions, budgeting and buying patterns of customers and other factors. Fluctuations in our revenue and operating results could also cause our stock price to decline.

In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price, or for other reasons. Securities litigation brought against us following volatility in our stock price or otherwise, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management’s attention and resources from our business.

These and other factors may make the price of our stock volatile and subject to unexpected fluctuation.

45

Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions include that:

●    our board of directors has the right to expand the size of our board of directors and to elect directors to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;

●    our stockholders may not act by written consent or call special stockholders’ meetings; as a result, a holder, or holders, controlling a majority of our capital stock would not be able to take certain actions other than at annual stockholders’ meetings or special stockholders’ meetings called by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, the chairman of the board or the chief executive officer;

●    our amended and restated certificate of incorporation prohibits cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

●    the affirmative vote of holders of at least 66-2/3% of the voting power of all of the then outstanding shares of voting stock, voting as a single class, will be required (a) to amend certain provisions of our certificate of incorporation, including provisions relating to the size of the board, special meetings, actions by written consent and cumulative voting and (b) to amend or repeal our amended and restated bylaws, although such bylaws may be amended by a simple majority vote of our board of directors;

●    stockholders must provide advance notice and additional disclosures to nominate individuals for election to the board of directors or to propose matters that can be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of our company; and

●    our board of directors may issue, without stockholder approval, shares of undesignated preferred stock; the ability to issue undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:

●    any derivative action or proceeding brought on our behalf;

46

●    any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders;

●    any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; and

●    any action asserting a claim against us that is governed by the internal-affairs doctrine.

This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.

These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.

General Risk Factors

Unfavorable economic and market conditions, domestically and internationally, may adversely affect our business, financial condition, results of operations and cash flows.

We have significant customer sales both in the United States and internationally. We also rely on domestic and international suppliers, manufacturing partners and distributors. We are therefore susceptible to adverse U.S. and international economic and market conditions. If any of our manufacturing partners, customers, distributors or suppliers experience slowdowns in their business, serious financial difficulties or cease operations, including as a result of the COVID-19 pandemic, our business will be adversely affected. In addition, the adverse impact of general economic factors that are beyond our control, including, but not limited to, housing markets, recession, inflation, deflation, consumer credit activity, consumer debt levels, fuel and energy costs, interest rates, tax rates and policy, unemployment trends, the impact of natural disasters such as pandemics, civil disturbances, and terrorist activities may adversely impact consumer spending, which may adversely impact our customers’ spending and demand for our products.

Our business may be adversely impacted by natural disasters and other catastrophic events.

Our operations and business, and those of our manufacturing partners, customers, distributors or suppliers, can be disrupted by natural disasters; industrial accidents; public health issues, such as the COVID-19 pandemic; cybersecurity incidents; interruptions of service from utilities, transportation, telecommunications, or IT systems providers; manufacturing equipment failures; or other catastrophic events. For example, some of our foundries and suppliers’ facilities in Asia are located near known earthquake fault zones and, therefore, are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, such as power loss, fire, floods and similar events. If any such natural disasters or other catastrophic events were to occur, our ability to operate our business could be seriously impaired. In addition, we may not have adequate insurance to cover our losses resulting from disasters or other similar significant business interruptions. Any significant losses that are not recoverable under our insurance policies could seriously impair our business and financial condition.

47

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

48

Item 6. Exhibits

EXHIBIT INDEX

		Incorporation By Reference
Exhibit Number	Description	Form	SEC File No.	Exhibit/ Reference	Filing Date
3.1	Amended and Restated Certificate of Incorporation	8-K	001-37900	3.1	10/13/2016
3.1.1	Amendment to Amended and Restated Certificate of Incorporation	8-K	001-37900	3.1	5/22/2019
3.1.2	Amendment to Amended and Restated Certificate of Incorporation	8-K	001-37900	3.1	5/27/2020
3.2	Amended and Restated Bylaws	8-K	001-37900	3.2	5/22/2019
10.1	Executive Employment Agreement, effective as of April 3, 2021, between Everspin Technologies, Inc. and Sanjeev Aggarwal	8-K	001-37900	10.1	7/22/2021
10.2	Executive Employment Agreement, effective as of July 2, 2021, between Everspin Technologies, Inc. and Anuj Aggarwal	8-K	001-37900	10.2	7/22/2021
10.3	Second Amendment to Amended and Restated Loan and Security Agreement, dated as of July 28, 2021, between the Company and Silicon Valley Bank	10-Q	001-37900	10.5	8/12/2021
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act

49

32.1**	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*     Filed herewith.

**   Furnished herewith. Exhibit 32.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise specifically stated in such filing.

50

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Everspin Technologies, Inc.
Date: November 12, 2021	By:	/s/ Darin Billerbeck
		Darin Billerbeck
		Interim Chief Executive Officer
		(Principal Executive Officer)
Date: November 12, 2021	By:	/s/ Anuj Aggarwal
		Anuj Aggarwal
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

51

EX-31.1

Exhibit 31.1

Certification of the Principal Executive Officer

I, Darin Billerbeck, certify that:

1. I have reviewed this Form 10-Q of Everspin Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 12, 2021

/s/ Darin Billerbeck

Darin Billerbeck

Interim Chief Executive Officer

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer

I, Anuj Aggarwal, certify that:

1. I have reviewed this Form 10-Q of Everspin Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 12, 2021

/s/Anuj Aggarwal

Anuj Aggarwal

Chief Financial Officer

(Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Darin Billerbeck, Interim Chief Executive Officer of Everspin Technologies, Inc. (the “Company”), and Anuj Aggarwal, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2021

/s/ Darin Billerbeck

Darin Billerbeck

Interim Chief Executive Officer

(Principal Executive Officer)

/s/ Anuj Aggarwal

Anuj Aggarwal

Chief Financial Officer

(Principal Financial Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Everspin Technologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 11, 2021
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Entity File Number	001-37900
Entity Registrant Name	Everspin Technologies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-2640654
Entity Address, Address Line One	5670 W. Chandler Boulevard
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Chandler
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85226
City Area Code	480
Local Phone Number	347-1111
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	MRAM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,608,354
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001438423
Amendment Flag	false

XML

Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 14,558	$ 14,599
Accounts receivable, net	10,629	7,607
Inventory	6,668	5,721
Prepaid expenses and other current assets	337	270
Total current assets	32,192	28,197
Property and equipment, net	951	1,946
Right-of-use assets	1,270	2,313
Other assets	488	73
Total assets	34,901	32,529
Current liabilities:
Accounts payable	2,663	2,224
Accrued liabilities	2,523	2,232
Deferred revenue	1,382
Current portion of long-term debt	3,364	4,242
Operating lease liabilities	1,011	1,508
Other liabilities	36	31
Total current liabilities	10,979	10,237
Long-term debt, net of current portion	2,100	3,748
Operating lease liabilities, net of current portion	268	903
Long-term income tax liability	229	229
Total liabilities	13,576	15,117
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2021 and December 31, 2020
Common stock, $0.0001 par value per share; 100,000,000 shares authorized; 19,552,125 and 19,031,556 shares issued and outstanding as of September 30, 2021 and December 31, 2020	2	2
Additional paid-in capital	177,821	174,584
Accumulated deficit	(156,498)	(157,174)
Total stockholders' equity	21,325	17,412
Total liabilities and stockholders' equity	$ 34,901	$ 32,529

XML

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Balance Sheets
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	19,552,125	19,031,556
Common stock, shares outstanding	19,552,125	19,031,556

XML

Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total revenue	$ 14,795	$ 10,120	$ 36,923	$ 32,054
Cost of sales	6,347	7,791	15,294	19,183
Gross profit	8,448	2,329	21,629	12,871
Operating expenses:
Research and development	3,105	2,579	8,901	8,383
General and administrative	2,996	2,549	8,177	7,797
Sales and marketing	1,272	912	3,304	3,071
Total operating expenses	7,373	6,040	20,382	19,251
Income (loss) from operations	1,075	(3,711)	1,247	(6,380)
Interest expense	(165)	(157)	(461)	(501)
Other (expense) income, net	(8)	(3)	(35)	60
Net income (loss) before income taxes	902	(3,871)	751	(6,821)
Income tax expense	(22)	(24)	(75)	(100)
Net income (loss) and comprehensive income (loss)	$ 880	$ (3,895)	$ 676	$ (6,921)
Net income (loss) per share attributable to common share, basic	$ 0.05	$ (0.21)	$ 0.03	$ (0.37)
Net income (loss) per share attributable to common stockholders, diluted	$ 0.04	$ (0.21)	$ 0.03	$ (0.37)
Weighted average common shares used to compute net income (loss) per common share attributable to common stockholders, basic	19,511,132	18,942,163	19,296,241	18,705,149
Weighted average common shares used to compute net income (loss) per common share attributable to common stockholders, diluted	19,912,918	18,942,163	19,787,889	18,705,149
Product sales
Total revenue	$ 12,037	$ 9,577	$ 31,292	$ 30,139
Cost of sales	6,043	7,763	14,629	19,009
Licensing, royalty and other revenue
Total revenue	2,758	543	5,631	1,915
Cost of sales	$ 304	$ 28	$ 665	$ 174

XML

Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses include stock-based compensation as follows:
Total stock-based compensation	$ 1,027	$ 910	$ 2,474	$ 2,633
Research and Development [Member]
Operating expenses include stock-based compensation as follows:
Total stock-based compensation	428	182	874	538
General and Administrative [Member]
Operating expenses include stock-based compensation as follows:
Total stock-based compensation	434	657	1,224	1,888
Sales and Marketing [Member]
Operating expenses include stock-based compensation as follows:
Total stock-based compensation	$ 165	$ 71	$ 376	$ 207

XML

Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 2	$ 167,149	$ (148,662)	$ 18,489
Balance (in shares) at Dec. 31, 2019	18,081,753
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under stock incentive plans		315		315
Issuance of common stock under stock incentive plans (in shares)	88,375
Stock-based compensation expense		805		805
Issuance of common stock in at-the-market offering, net of issuance costs		2,084		2,084
Issuance of common stock in at-the-market offering, net of issuance costs (in shares)	468,427
Net income (loss)			(1,732)	(1,732)
Balance at Mar. 31, 2020	$ 2	170,353	(150,394)	19,961
Balance (in shares) at Mar. 31, 2020	18,638,555
Balance at Dec. 31, 2019	$ 2	167,149	(148,662)	18,489
Balance (in shares) at Dec. 31, 2019	18,081,753
Increase (Decrease) in Stockholders' Equity
Net income (loss)				(6,921)
Balance at Sep. 30, 2020	$ 2	173,539	(155,583)	17,958
Balance (in shares) at Sep. 30, 2020	18,970,791
Balance at Mar. 31, 2020	$ 2	170,353	(150,394)	19,961
Balance (in shares) at Mar. 31, 2020	18,638,555
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under stock incentive plans		827		827
Issuance of common stock under stock incentive plans (in shares)	231,220
Stock-based compensation expense		918		918
Net income (loss)			(1,294)	(1,294)
Balance at Jun. 30, 2020	$ 2	172,098	(151,688)	20,412
Balance (in shares) at Jun. 30, 2020	18,869,775
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under stock incentive plans		379		379
Issuance of common stock under stock incentive plans (in shares)	101,016
Stock-based compensation expense		910		910
Issuance of warrant		152		152
Net income (loss)			(3,895)	(3,895)
Balance at Sep. 30, 2020	$ 2	173,539	(155,583)	17,958
Balance (in shares) at Sep. 30, 2020	18,970,791
Balance at Dec. 31, 2020	$ 2	174,584	(157,174)	17,412
Balance (in shares) at Dec. 31, 2020	19,031,556
Increase (Decrease) in Stockholders' Equity
Exercise of stock options		144		144
Exercise of stock options (in shares)	54,077
Issuance of common stock under stock incentive plans		364		364
Issuance of common stock under stock incentive plans (in shares)	136,709
Stock-based compensation expense		743		743
Net income (loss)			(460)	(460)
Balance at Mar. 31, 2021	$ 2	175,835	(157,634)	18,203
Balance (in shares) at Mar. 31, 2021	19,222,342
Balance at Dec. 31, 2020	$ 2	174,584	(157,174)	$ 17,412
Balance (in shares) at Dec. 31, 2020	19,031,556
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)				104,743
Net income (loss)				$ 676
Balance at Sep. 30, 2021	$ 2	177,821	(156,498)	21,325
Balance (in shares) at Sep. 30, 2021	19,552,125
Balance at Mar. 31, 2021	$ 2	175,835	(157,634)	18,203
Balance (in shares) at Mar. 31, 2021	19,222,342
Increase (Decrease) in Stockholders' Equity
Exercise of stock options		57		57
Exercise of stock options (in shares)	23,280
Issuance of common stock under stock incentive plans		92		92
Issuance of common stock under stock incentive plans (in shares)	189,652
Stock-based compensation expense		704		704
Net income (loss)			256	256
Balance at Jun. 30, 2021	$ 2	176,688	(157,378)	19,312
Balance (in shares) at Jun. 30, 2021	19,435,274
Increase (Decrease) in Stockholders' Equity
Exercise of stock options		106		106
Exercise of stock options (in shares)	27,386
Issuance of common stock under stock incentive plans (in shares)	68,002
Stock-based compensation expense		1,027		1,027
Exercise of warrants (in shares)	21,463
Net income (loss)			880	880
Balance at Sep. 30, 2021	$ 2	$ 177,821	$ (156,498)	$ 21,325
Balance (in shares) at Sep. 30, 2021	19,552,125

XML

Statement of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ 676	$ (6,921)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	1,117	1,611
Stock-based compensation	2,474	2,633
Non-cash warrant revaluation	5	2
Non-cash interest expense	274	231
Changes in operating assets and liabilities:
Accounts receivable	(3,022)	(2,368)
Inventory	(947)	1,690
Prepaid expenses and other current assets	(67)	440
Other assets	(175)
Accounts payable	656	(31)
Accrued liabilities	655	(692)
Deferred revenue	1,382
Lease liabilities	(90)	(132)
Net cash provided by (used in) operating activities	2,938	(3,537)
Cash flows from investing activities
Purchases of property and equipment	(578)	(307)
Net cash used in investing activities	(578)	(307)
Cash flows from financing activities
Payments on long-term debt	(2,800)
Payments on finance lease obligation		(6)
Proceeds from exercise of stock options and purchase of shares in employee stock purchase plan	399	1,206
Proceeds from issuance of common stock in at-the-market offering, net of issuance costs		2,084
Net cash (used in) provided by financing activities	(2,401)	3,284
Net decrease in cash and cash equivalents	(41)	(560)
Cash and cash equivalents at beginning of period	14,599	14,487
Cash and cash equivalents at end of period	14,558	13,927
Supplementary cash flow information:
Interest paid	178	271
Operating cash flows paid for operating leases	1,212	1,298
Financing cash flows paid for finance leases		6
Non-cash investing and financing activities:
Increase of right-of-use asset and lease liability due to lease modification		545
Purchases of property and equipment in accounts payable and accrued liabilities		8
Bonus settled in shares of common stock	$ 364	315
Issuance of warrant with debt		$ 152

XML

Organization and Nature of Business

9 Months Ended

Sep. 30, 2021

Organization and Nature of Business

Organization and Nature of Business

1. Organization and Nature of Business

Everspin Technologies, Inc. (the Company) was incorporated in Delaware on May 16, 2008. The Company’s magnetoresistive random-access memory (MRAM) solutions offer the persistence of non-volatile memory with the speed and endurance of random-access memory (RAM) and enable the protection of mission critical data particularly in the event of power interruption or failure. The Company’s MRAM solutions allow its customers in the industrial, medical, automotive/transportation, aerospace and data center markets to design high performance, power efficient and reliable systems without the need for bulky batteries or capacitors.

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2021

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information required by GAAP for complete financial statements. These unaudited interim condensed financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company’s financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any other future year.

The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the SEC.

The Company believes that its existing cash and cash equivalents as of September 30, 2021, coupled with its anticipated growth and sales levels will be sufficient to meet its anticipated cash requirements for at least the next twelve months from the financial statement issuance date. The Company’s future capital requirements will depend on many factors, including, among other things, its growth rate, the timing and extent of its spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the introduction of new products. The Company may be required at some point in the future to seek additional equity or debt financing, to sustain operations beyond that point, and such additional financing may not be available on acceptable terms or at all. If the Company is unable to raise additional capital or generate sufficient cash from operations to adequately fund its operations, it will need to curtail planned activities to reduce costs. Doing so will likely harm its ability to execute on its business plan.

Prior Period Reclassifications

Certain immaterial prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, fair value of assets and liabilities, inventory reserves, product warranty reserves, deferred tax assets and

related valuation allowances, and stock-based compensation. The Company believes its estimates and assumptions are reasonable; however, actual results may differ from the Company’s estimates.

Accounts receivable, net

The Company establishes an allowance for product returns. The Company analyzes historical returns, current economic trends and changes in customer demand and acceptance of products when evaluating the adequacy of sales returns. Returns are processed as credits on future purchases, and as a result, the allowance is recorded against the balance of trade accounts receivable. In addition, the Company establishes an allowance for estimated price concessions related to its distributor agreements. The Company estimates credits to distributors based on the historical rate of credits provided to distributors relative to sales.

Accounts receivable, net consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Trade accounts receivable	$	10,500	$	7,590
Unbilled accounts receivable		344		255
Allowance for product returns and price concessions		(215)		(238)
Accounts receivable, net	$	10,629	$	7,607

Concentration of Credit Risk

Financial instruments that potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents that are held by a financial institution in the United States and accounts receivable. Amounts on deposit with a financial institution may at times exceed federally insured limits. The Company maintains its cash accounts with high credit quality financial institutions and, accordingly, minimal credit risk exists with respect to the financial institutions.

Significant customers are those which represent more than 10% of the Company’s total revenue or net accounts receivable balance at each respective balance sheet date. For the purposes of this disclosure, the Company defines “customer” as the entity that is purchasing the products or licenses directly from the Company, which includes the distributors of the Company’s products in addition to end customers that the Company sells to directly. For each significant customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable, net are as follows:

	Revenue								Accounts Receivable, net
	Three Months Ended				Nine Months Ended				As of
	September 30,				September 30,				September 30,		December 31,
Customers	2021		2020		2021		2020		2021		2020
Customer A	17	%	38	%	14	%	32	%	21	%	29	%
Customer B	13	%	*		20	%	*		31	%	25	%
Customer C	*		*		*		*		12	%	*

* Less than 10%

Fair Value of Financial Instruments

Fair value is defined as an exit price, representing the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. The framework for measuring fair value provides a three-tier hierarchy prioritizing inputs to valuation techniques used in measuring fair value as follows:

Level 1— Observable inputs such as quoted prices for identical assets or liabilities in active markets;

Level 2— Inputs, other than quoted prices for identical assets or liabilities in active markets, which are observable either directly or indirectly; and

Level 3— Unobservable inputs in which there is little or no market data requiring the reporting entity to develop its own assumptions.

As of September 30, 2021, based on Level 2 inputs and the borrowing rates available to the Company for loans with similar terms and consideration of the Company’s credit risk, the carrying value of the Company’s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value. The Company’s financial instruments consist of Level 1 assets and a Level 3 liability. Level 1 assets consist of highly liquid money market funds that are included in cash equivalents. The Company’s Level 3 liability consists of warrants issued in connection with the Company’s current credit facility (Note 6).

The following tables sets forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	September 30, 2021
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,657	$	—	$	—	$	14,657
Total assets measured at fair value	$	14,657	$	—	$	—	$	14,657
Liabilities:
Warrant liability	$	—	$	—	$	36	$	36
Total liabilities measured at fair value	$	—	$	—	$	36	$	36

	December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,669	$	—	$	—	$	14,669
Total assets measured at fair value	$	14,669	$	—	$	—	$	14,669
Liabilities:
Warrant liability	$	—	$	—	$	31	$	31
Total liabilities measured at fair value	$	—	$	—	$	31	$	31

Recently Issued Pronouncements

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. As the Company is a smaller reporting company, ASU 2016-13 is effective for the Company’s annual reporting periods, and interim periods within those years, beginning after December 15, 2022, and requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements Financial Instruments-Credit Losses (Topic 326). The new ASU provides narrow-scope amendments to help apply ASU No. 2016-13. The Company is evaluating the impact of the adoption of ASU 2016-13 and ASU 2019-04 on its financial statements.

XML

Revenue

9 Months Ended

Sep. 30, 2021

Revenue.

Revenue

3. Revenue

The Company sells the majority of its products to distributors and original equipment manufacturers (OEMs). The Company also recognizes revenue under manufacturing and engineering service agreements and licensing and royalty agreements with some customers.

The following table presents the Company’s revenues disaggregated by sales channel (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Distributor	$	9,143	$	5,385	$	24,644	$	18,952
Non-distributor		5,652		4,735		12,279		13,102
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

The following table presents the Company’s revenues disaggregated by timing of recognition (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Point in time	$	13,618	$	9,756	$	34,212	$	30,982
Over time		1,177		364		2,711		1,072
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

The following table presents the Company’s revenues disaggregated by type (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Product sales	$	12,037	$	9,577	$	31,292	$	30,139
Royalties		274		179		1,612		843
Patents		1,307		—		1,307		—
Other revenue		1,177		364		2,712		1,072
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

In September 2021, the Company entered into an intellectual property monetization deal to sell five patents to a customer for a total contract value of $5.25 million. Two of the patents were assigned to the customer in September 2021, and the remaining three patents were assigned to the customer subsequent to quarter-end in October 2021. Control is transferred when the patents are assigned to the customer. As a result, $1.30 million of patent revenue was recognized during the quarter ended September 31, 2021, related to the patent sales, with the remaining $3.95 million to be recognized in the fourth quarter of 2021.

The Company recognizes revenue in three primary geographic regions: Asia-Pacific (APAC); North America; and Europe, Middle East and Africa (EMEA). The following table presents the Company’s revenues disaggregated by the geographic region to which the product is delivered or licensee is located (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
APAC	$	8,523	$	7,152	$	23,474	$	22,435
North America		4,197		2,109		8,623		5,033
EMEA		2,075		859		4,826		4,586
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

XML

Balance Sheet Components

9 Months Ended

Sep. 30, 2021

Balance Sheet Components

Balance Sheet Components

4. Balance Sheet Components

Inventory

Inventory consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Raw materials	$	356	$	329
Work-in-process		5,084		4,910
Finished goods		1,228		482
Total inventory	$	6,668	$	5,721

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Payroll-related expenses	$	1,994	$	1,274
Inventory		266		416
Other		263		542
Total accrued liabilities	$	2,523	$	2,232

Deferred Revenue

In the nine months ended September 30, 2021, the Company executed contractual arrangements with a customer for the development of a RAD-Hard product, consisting of a technology license, design license agreement and development subcontract. The Company does not share in the rights to future revenues or royalties. The total arrangements are for $6.5 million in consideration.

The Company concluded these contractual arrangements represent one arrangement and evaluated its promises to the customer and whether the performance obligations granted under the arrangement were distinct.  The licenses provided to the customer are not transferable, are of limited value without the promised development services, and the customer cannot benefit from the license agreements without the specific obligated services in the development subcontract, as there is strong interdependency between the licenses and the development subcontract. Accordingly, the Company determined the licenses were not distinct within the context of the contract and combined the license with other performance obligations.

As a result, the Company is recognizing revenue related to the performance obligations over time using the input method based on costs incurred to date relative to the total expected costs of the contract and began recognizing revenue in the second quarter of 2021 over the performance obligation period.

Under the agreements, the Company received a non-refundable, upfront payment of $3.0 million in the first quarter of 2021 and a payment of $0.7 million was received in the third quarter of 2021. As of September 30, 2021, $1.4 million was recorded as deferred revenue, current, with $0.9 million and $2.3 million recognized as revenue during the three and nine months ended September 30, 2021, respectively.

XML

Leases

9 Months Ended

Sep. 30, 2021

Leases

Leases

5. Leases

Operating leases consist primarily of office space expiring at various dates through 2023. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The undiscounted future non-cancellable lease payments under the Company’s operating leases were as follows (in thousands):

As of September 30, 2021	Amount
2021	$	391
2022		861
2023		68
Total lease payments		1,320
Less: imputed interest		(41)
Total operating lease liabilities		1,279
Less: current portion of operating lease liabilities		(1,011)
Total operating lease liabilities, net of current portion	$	268

Other information related to the Company’s operating lease liabilities was as follows:

	September 30,		December 31,
	2021		2020
Weighted-average remaining lease term (years)	1.15		1.74
Weighted-average discount rate	6.00	%	6.00	%

In September 2021, and subsequent to quarter end in October 2021, the Company entered into two new office lease agreements for leases that were set to expire in the fourth quarter of 2021 and the first quarter of 2022. Both new lease agreements are scheduled to commence in February 2022. Monthly escalating lease payments range from $13,000 to $39,000, with maturity dates ranging from April 2027 – January 2029, both with options to extend upon written notice within twelve months prior to maturity.

XML

Debt

9 Months Ended

Sep. 30, 2021

Debt

Debt

6. Debt

2019 Credit Facility

In August 2019, the Company executed an Amended and Restated Loan and Security Agreement (2019 Credit Facility), which amended and restated the Company’s prior loan and security agreement (2017 Credit Facility), providing for a formula revolving line of credit (Line of Credit) and a term loan (2019 Term Loan) with Silicon Valley Bank (SVB) to refinance in full the outstanding principal balance of $8.0 million under the 2017 Credit Facility. In August 2019, the Company paid the final payment of $0.8 million, which was due upon the refinancing of the 2017 Credit Facility.

In July 2020, the Company executed the first amendment to the 2019 Credit Facility with SVB. The amendment, among other things, extended the initial 12-month interest-only period for the 2019 Term Loan to a 16-month interest-only period and lowered the floor interest rate. The floor interest rates for the 2019 Term Loan and the Line of Credit were reduced from 4.75% and 6.75% to 3.75% and 4.75%, respectively.

The amended Line of Credit allows for a maximum draw of $5.0 million, subject to a formula borrowing base, has a two-year term and bears interest at a floating rate equal to the Wall Street Journal (WSJ) prime rate plus 1.5%, per annum, subject to a floor of 4.75%. As of September 30, 2021, the interest rate was 4.75%. The Line of Credit required a commitment fee of 1.6% of the maximum availability of the Line of Credit, which was paid in August 2019 upon closing, and was accounted for as a debt discount. The Line of Credit also provides for a termination fee equal to 1% of the maximum availability under the Line of Credit, which is due in case of a termination of the Line of Credit prior to the scheduled maturity date, and an unused facility fee equal to 0.125% per annum of the average unused portion of the Line of Credit, which is expensed as incurred. At execution, $2.0 million from the Line of Credit was used to refinance a portion of the outstanding balance of the 2017 Credit Facility, and $3.0 million remains available under the Line of Credit, subject to borrowing base availability. As of September 30, 2021, the effective interest rate under the Line of Credit was 10.18% and the outstanding balance was $1.0 million. The Line of Credit was set to mature on August 5, 2021. The second amendment, entered into on July 28, 2021, extended the maturity date of the Line of Credit to August 5, 2022.

The amended 2019 Term Loan provides for a $6.0 million term loan, which was used to refinance the remaining balance of the 2017 Credit Facility. The 2019 Term Loan has a term of 46 months, and a 16-month interest-only period followed by 30 months of equal principal payments, plus accrued interest. The 2019 Term Loan bears interest at a floating rate equal to the WSJ prime rate minus 0.75%, subject to a floor of 3.75%. As of September 30, 2021, the interest rate was 3.75%. A final payment of 7% of the original principal amount of the 2019 Term Loan must be made when the 2019 Term Loan is prepaid or repaid, whether at maturity or as a result of a prepayment or acceleration or otherwise. The additional payment, which is accounted for as a debt discount, is being accreted using the effective interest method. The 2019 Term Loan has a prepayment fee equal to 2% of the total commitment, which is due only if the 2019 Term Loan is prepaid prior to the scheduled maturity date for any reason. As of September 30, 2021, the effective interest rate under the 2019 Term Loan was 7.85% and the outstanding balance was $4.6 million. The 2019 Term Loan matures on June 1, 2023.

In conjunction with entering into the 2019 Credit Facility, on August 5, 2019, the Company and SVB amended and restated the warrant issued to SVB in connection with the first amendment to the 2017 Credit Facility, which was a warrant to purchase 9,375 shares of the Company’s common stock at an exercise price of $8.91 per share, to add an option by SVB to put the warrant back to the Company for $50,000 upon expiration or a liquidity event, to be prorated if SVB exercises a portion of the warrant. The warrant expires on July 6, 2023. The warrant is classified as a liability and recorded at fair value within other liabilities in the Company’s condensed balance sheet. Due to the put right, the warrant is subject to fair value remeasurement at each subsequent reporting date until the exercise or expiration of the warrant. Any resulting change in the fair value of the warrant will be recorded as other (expense) income, net in the Company’s condensed statement of operations and comprehensive loss. The Company recognized other expense of $0 and $5,000 for the three and nine months ended September 30, 2021, respectively. The Company recognized other expense of $5,000 and $2,000 for the three and nine months ended September 30, 2020, respectively.

In conjunction with entering into the first amendment to the 2019 Credit Facility, on July 15, 2020, the Company issued a warrant to SVB to purchase 21,500 shares of the Company’s common stock at an exercise price of $0.01 per share. The warrant expires on July 15, 2025. The warrant is classified as equity and was recorded as a debt discount that will be amortized to interest expense using the effective interest method. The fair value of the warrant was $152,000 on the date of issuance using the Black-Scholes option-pricing model. On July 22, 2021, SVB elected to exercise the warrant associated with the first amendment to the 2019 Credit Facility, which resulted in a net cashless exercise of the warrant and the issuance of 21,463 shares of the Company’s common stock.

Collateral for the 2019 Credit Facility includes all of the Company’s assets except for intellectual property. The Company is required to comply with certain covenants under the 2019 Credit Facility, including requirements to maintain a minimum cash balance and availability under the Line of Credit, and restrictions on certain actions without the consent of the lender, such as limitations on its ability to engage in mergers or acquisitions, sell assets, incur indebtedness or grant liens or negative pledges on its assets, make loans or make other investments. Under these covenants, the Company is prohibited from paying cash dividends with respect to its capital stock. The Company was in compliance with all covenants at September 30, 2021. The 2019 Credit Facility contains a material adverse effect clause which provides that an event of default will occur if, among other triggers, an event occurs that could reasonably be expected to result in a material adverse effect on the Company’s business, operations or condition, or on the Company’s ability to perform its obligations under the 2019 Term Loan. As of September 30, 2021, management does not believe that it is probable that the clause will be triggered within the next 12 months, and therefore the 2019 Term Loan is classified as long-term debt.

The amortization of the debt issuance costs and accretion of the debt discount is included in interest expense within the statement of operations and comprehensive loss and included in non-cash interest expense within the statement of cash flows.

The carrying value of the Company’s 2019 Credit Facility as of September 30, 2021 was as follows (in thousands):

	Current		Long-Term
	Portion		Debt		Total
Credit Facility	$	3,400	$	2,220	$	5,620
Unamortized debt discounts		(36)		(120)		(156)
Net carrying value	$	3,364	$	2,100	$	5,464

The carrying value of the Company’s 2019 Credit Facility as of December 31, 2020 was as follows (in thousands):

	Current		Long-Term
	Portion		Debt		Total
Credit Facility	$	4,400	$	4,020	$	8,420
Unamortized debt discounts		(158)		(272)		(430)
Net carrying value	$	4,242	$	3,748	$	7,990

The table below includes the principal repayments due under the 2019 Credit Facility (in thousands):

	Principal Repayment as of September 30, 2021
2021 (three remaining months)		600
2022		3,400
2023		1,620
Total principal repayments	$	5,620

The $0.6 million in principal repayments noted above for the three remaining months for the year ended December 31, 2021 are related to payments on the Term Loan.

Of

XML

Stockholders' Equity

9 Months Ended

Sep. 30, 2021

Stockholders' Equity

Stockholders' Equity

7. Stockholders’ Equity

At-the-Market Sales Agreement

In August 2019, the Company entered into an Open Market Sale Agreement (2019 Sales Agreement) with Jefferies, LLC (Jefferies), for the offer and sale of shares of its common stock having an aggregate offering of up to $25.0 million from time to time through Jefferies, acting as the Company’s sales agent. The issuance and sale of these shares by the Company pursuant to the 2019 Sales Agreement are deemed an “at-the-market” (ATM) offering under the Securities Act of 1933, as amended. Under the 2019 Sales Agreement, the Company agreed to pay Jefferies a commission of up to 3% of the gross proceeds of any sales made pursuant to the Sales Agreement. During the nine months ended September 30, 2020, the Company received net proceeds of $2.1 million, after deducting commissions and expenses payable by the Company, from the sale of 468,427 shares of common stock pursuant to the 2019 Sales Agreement. The Company suspended sales under the 2019 Sales Agreement in March 2020 and terminated the ATM program in November 2020.

XML

Stock-Based Compensation

9 Months Ended

Sep. 30, 2021

Stock-Based Compensation

Stock-Based Compensation

8. Stock-Based Compensation

The following table summarizes the stock option and award activity for the nine months ended September 30, 2021:

		Options Outstanding
			Weighted-		Weighted-
	Options and		Average		Average	Aggregate
	Awards		Exercise		Remaining	Intrinsic
	Available for	Number of	Price Per		Contractual	Value
	Grant	Options	Share		Life (years)	(In thousands)
Balance—December 31, 2020	179,219	2,272,905	$	5.58	7.9	$	1,640
Authorized	1,120,946
RSUs granted	(517,564)
RSUs cancelled/forfeited	108,581
Options granted	(744,978)	744,978	$	5.60
Options exercised	—	(104,743)	$	2.94		$	346
Options cancelled/forfeited	897,471	(916,911)	$	6.49
Balance—September 30, 2021	1,043,675	1,996,229	$	5.30	8.3	$	2,951
Options exercisable—September 30, 2021		760,979	$	6.01	6.8	$	895

The total grant date fair value of options vested was $178,000 and $438,000 during the three months ended September 30, 2021 and 2020, respectively, and $711,000 and $1.8 million during the nine months ended September 30, 2021 and 2020, respectively.

The weighted-average grant date fair value of employee options granted was $3.59 and $3.62 per share during the three months ended September 30, 2021 and 2020, respectively, and $3.58 and $1.71 per share during the nine months ended September 30, 2021 and 2020, respectively.

As of September 30, 2021, of the 916,911 options cancelled/forfeited, 19,440 of the options relate to a prior stock-based compensation plan that are no longer available for grant under the current stock-based compensation plan.

2016 Employee Stock Purchase Plan

In January 2021, there was an increase of 190,315 shares reserved for issuance under the Company’s Employee Stock Purchase Plan (ESPP) pursuant to the terms of the ESPP. The Company had 684,996 shares available for future issuance under the Company’s ESPP as of September 30, 2021. Employees purchased 32,186 shares for $92,000 during the nine months ended September 30, 2021. Employees purchased 22,474 shares for $50,000 during the three and nine months ended September 30, 2020.

Restricted Stock Units

The following table summarizes restricted stock units (RSUs) activity for the nine months ended September 30, 2021:

	RSUs Outstanding
		Weighted-
		Average
	Number of	Grant Date
	Restricted Stock	Fair Value Per
	Units	Share
Balance—December 31, 2020	416,742	$	4.89
Granted	517,564	$	5.51
Vested	(362,438)	$	5.62
Cancelled/forfeited	(108,581)	$	4.75
Balance—September 30, 2021	463,287	$	5.05

The fair value of RSUs is determined on the date of grant based on the market price of the Company’s common stock on that date. As of September 30, 2021, there was $1.9 million of unrecognized stock-based compensation expense related to RSUs to be recognized over a weighted-average period of 2.2 years.

Stock-based Compensation Expense

As of September 30, 2021, there was $3.5 million of total unrecognized stock-based compensation expense related to unvested options which is expected to be recognized over a weighted-average period of 3.0 years.

XML

Significant Agreements

9 Months Ended

Sep. 30, 2021

Significant Agreements

Significant Agreements

9. Significant Agreements

GLOBALFOUNDRIES, Inc. Joint Development Agreement

Since October 17, 2014, the Company has participated in a joint development agreement (JDA) with GLOBALFOUNDRIES Inc. (GF), a semiconductor foundry, for the joint development of Spin-transfer Torque MRAM (STT-MRAM), technology to produce a family of discrete and embedded MRAM technologies. The term of the agreement is until the completion, termination, or expiration of the last statement of work entered into pursuant to the joint development agreement. The Company entered into a Statement of Work (SOW) and an Amendment to the SOW, under the JDA with GF effective August 2016 and June 2018, respectively. The agreement was extended on December 31, 2019 to include a new phase of support for 12nm MRAM development.

Under the current JDA extension terms, each party licenses its relevant intellectual property to the other party. For certain jointly developed works, the parties have agreed to follow an invention allocation procedure to determine ownership. In addition, GF possesses the exclusive right to manufacture the Company’s discrete and embedded STT-MRAM devices developed pursuant to the agreement until the earlier of three years after the qualification of the MRAM device for a particular technology node or four years after the completion of the relevant statement of work under which the device was developed. For the same exclusivity period associated with the relevant device, GF agreed not to license intellectual property developed in connection with the JDA to named competitors of the Company.

Generally, unless otherwise specified in the agreement or a statement of work, the Company and GF share project costs, which do not include personnel or production qualification costs, under the JDA. If GF manufactures, sells or transfers to customers wafers containing production quantified STT-MRAM devices that utilize certain design information, GF will be required to pay the Company a royalty.

Silterra Malaysia Sdn. Bhd. Joint Collaboration Agreement

In September 2018, the Company entered into a Joint Collaboration Agreement (JCA) with Silterra Malaysia Sdn. Bhd., and another third party. The JCA will create additional manufacturing capacity for the Company’s Toggle MRAM products. The Company had previously anticipated initial production starting in 2020. However, as a result of recent delays, the Company now anticipates initial production to start some time in 2022. Under the JCA, the Company is required to pay non-recurring engineering costs of $1.0 million. As of September 30, 2021, the Company has paid $600,000 of these JCA costs. There were no JCA costs paid during the nine months ended September 30, 2021. Subsequent to September 30, 2021, on October 23, 2021, the Company executed a termination of the JCA. As a result, the Company does not expect to incur additional JCA costs for the remainder of 2021.

XML

Net Income (Loss) Per Common Share

9 Months Ended

Sep. 30, 2021

Net Income (Loss) Per Common Share

Net Income (Loss) Per Common Share

10. Net Income (Loss) Per Common Share

Basic earnings per share is calculated by dividing net income by the weighted average shares outstanding. Diluted earnings per share is calculated using the treasury stock method by dividing net income by the total weighted average shares of common stock outstanding in addition to the potential impact of dilutive securities including restricted stock units, warrants, and options.

The following tables set forth the computation of basic and diluted net income (loss) per share attributable to common stockholders (in thousands, except share and per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Numerator:
Net income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Denominator:
Weighted-average common shares outstanding used to calculate net income (loss) per common share, basic		19,511,132		18,942,163		19,296,241		18,705,149
Net income (loss) per common share, basic	$	0.05	$	(0.21)	$	0.03	$	(0.37)

	Three Months Ended September 30,				Nine Months Ended September 30,
	September 30,				September 30,
	2021		2020		2021		2020
Numerator:
Net income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Denominator:
Weighted-average common shares outstanding used to calculate net income (loss) per common share, basic		19,511,132		18,942,163		19,296,241		18,705,149
Effect of dilutive		401,786		—		491,648		—
Weighted-average common shares outstanding used to calculate net income (loss) per common share, diluted		19,912,918		18,942,163		19,787,889		18,705,149
Net income (loss) per common share, diluted	$	0.04	$	(0.21)	$	0.03	$	(0.37)

The following outstanding shares of potentially dilutive securities have been excluded from diluted net income (loss) per common share for the periods presented, because their inclusion would be anti-dilutive:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2021	2020	2021	2020
Options to purchase common stock	1,251,209	2,300,452	1,277,088	2,300,452
RSUs	6,437	458,324	28,389	458,324
Common stock warrants	9,375	49,336	9,375	49,336
ESPP	14,031	—	28,078	—
Total	1,281,052	2,808,112	1,342,930	2,808,112

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2021

Summary of Significant Accounting Policies

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information required by GAAP for complete financial statements. These unaudited interim condensed financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair statement of the Company’s financial information. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any other future year.

The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the SEC.

The Company believes that its existing cash and cash equivalents as of September 30, 2021, coupled with its anticipated growth and sales levels will be sufficient to meet its anticipated cash requirements for at least the next twelve months from the financial statement issuance date. The Company’s future capital requirements will depend on many factors, including, among other things, its growth rate, the timing and extent of its spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the introduction of new products. The Company may be required at some point in the future to seek additional equity or debt financing, to sustain operations beyond that point, and such additional financing may not be available on acceptable terms or at all. If the Company is unable to raise additional capital or generate sufficient cash from operations to adequately fund its operations, it will need to curtail planned activities to reduce costs. Doing so will likely harm its ability to execute on its business plan.

Prior Period Reclassifications

Prior Period Reclassifications

Certain immaterial prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, fair value of assets and liabilities, inventory reserves, product warranty reserves, deferred tax assets and

related valuation allowances, and stock-based compensation. The Company believes its estimates and assumptions are reasonable; however, actual results may differ from the Company’s estimates.

Accounts receivable, net

Accounts receivable, net

The Company establishes an allowance for product returns. The Company analyzes historical returns, current economic trends and changes in customer demand and acceptance of products when evaluating the adequacy of sales returns. Returns are processed as credits on future purchases, and as a result, the allowance is recorded against the balance of trade accounts receivable. In addition, the Company establishes an allowance for estimated price concessions related to its distributor agreements. The Company estimates credits to distributors based on the historical rate of credits provided to distributors relative to sales.

Accounts receivable, net consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Trade accounts receivable	$	10,500	$	7,590
Unbilled accounts receivable		344		255
Allowance for product returns and price concessions		(215)		(238)
Accounts receivable, net	$	10,629	$	7,607

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents that are held by a financial institution in the United States and accounts receivable. Amounts on deposit with a financial institution may at times exceed federally insured limits. The Company maintains its cash accounts with high credit quality financial institutions and, accordingly, minimal credit risk exists with respect to the financial institutions.

Significant customers are those which represent more than 10% of the Company’s total revenue or net accounts receivable balance at each respective balance sheet date. For the purposes of this disclosure, the Company defines “customer” as the entity that is purchasing the products or licenses directly from the Company, which includes the distributors of the Company’s products in addition to end customers that the Company sells to directly. For each significant customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable, net are as follows:

	Revenue								Accounts Receivable, net
	Three Months Ended				Nine Months Ended				As of
	September 30,				September 30,				September 30,		December 31,
Customers	2021		2020		2021		2020		2021		2020
Customer A	17	%	38	%	14	%	32	%	21	%	29	%
Customer B	13	%	*		20	%	*		31	%	25	%
Customer C	*		*		*		*		12	%	*

* Less than 10%

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair value is defined as an exit price, representing the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. The framework for measuring fair value provides a three-tier hierarchy prioritizing inputs to valuation techniques used in measuring fair value as follows:

Level 1— Observable inputs such as quoted prices for identical assets or liabilities in active markets;

Level 2— Inputs, other than quoted prices for identical assets or liabilities in active markets, which are observable either directly or indirectly; and

Level 3— Unobservable inputs in which there is little or no market data requiring the reporting entity to develop its own assumptions.

As of September 30, 2021, based on Level 2 inputs and the borrowing rates available to the Company for loans with similar terms and consideration of the Company’s credit risk, the carrying value of the Company’s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value. The Company’s financial instruments consist of Level 1 assets and a Level 3 liability. Level 1 assets consist of highly liquid money market funds that are included in cash equivalents. The Company’s Level 3 liability consists of warrants issued in connection with the Company’s current credit facility (Note 6).

The following tables sets forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	September 30, 2021
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,657	$	—	$	—	$	14,657
Total assets measured at fair value	$	14,657	$	—	$	—	$	14,657
Liabilities:
Warrant liability	$	—	$	—	$	36	$	36
Total liabilities measured at fair value	$	—	$	—	$	36	$	36

	December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,669	$	—	$	—	$	14,669
Total assets measured at fair value	$	14,669	$	—	$	—	$	14,669
Liabilities:
Warrant liability	$	—	$	—	$	31	$	31
Total liabilities measured at fair value	$	—	$	—	$	31	$	31

Recently Issued Pronouncements

Recently Issued Pronouncements

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. As the Company is a smaller reporting company, ASU 2016-13 is effective for the Company’s annual reporting periods, and interim periods within those years, beginning after December 15, 2022, and requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements Financial Instruments-Credit Losses (Topic 326). The new ASU provides narrow-scope amendments to help apply ASU No. 2016-13. The Company is evaluating the impact of the adoption of ASU 2016-13 and ASU 2019-04 on its financial statements.

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2021

Summary of Significant Accounting Policies

Schedule of accounts receivable net

Accounts receivable, net consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Trade accounts receivable	$	10,500	$	7,590
Unbilled accounts receivable		344		255
Allowance for product returns and price concessions		(215)		(238)
Accounts receivable, net	$	10,629	$	7,607

Schedule of revenue and accounts receivable for each significant customer

	Revenue								Accounts Receivable, net
	Three Months Ended				Nine Months Ended				As of
	September 30,				September 30,				September 30,		December 31,
Customers	2021		2020		2021		2020		2021		2020
Customer A	17	%	38	%	14	%	32	%	21	%	29	%
Customer B	13	%	*		20	%	*		31	%	25	%
Customer C	*		*		*		*		12	%	*

* Less than 10%

Schedule of fair value of financial assets and liabilities measured on recurring basis

The following tables sets forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	September 30, 2021
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,657	$	—	$	—	$	14,657
Total assets measured at fair value	$	14,657	$	—	$	—	$	14,657
Liabilities:
Warrant liability	$	—	$	—	$	36	$	36
Total liabilities measured at fair value	$	—	$	—	$	36	$	36

	December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	14,669	$	—	$	—	$	14,669
Total assets measured at fair value	$	14,669	$	—	$	—	$	14,669
Liabilities:
Warrant liability	$	—	$	—	$	31	$	31
Total liabilities measured at fair value	$	—	$	—	$	31	$	31

XML

Revenue (Tables)

9 Months Ended

Sep. 30, 2021

Revenue.

Schedule of disaggregation of revenue

The following table presents the Company’s revenues disaggregated by sales channel (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Distributor	$	9,143	$	5,385	$	24,644	$	18,952
Non-distributor		5,652		4,735		12,279		13,102
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

The following table presents the Company’s revenues disaggregated by timing of recognition (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Point in time	$	13,618	$	9,756	$	34,212	$	30,982
Over time		1,177		364		2,711		1,072
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

The following table presents the Company’s revenues disaggregated by type (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Product sales	$	12,037	$	9,577	$	31,292	$	30,139
Royalties		274		179		1,612		843
Patents		1,307		—		1,307		—
Other revenue		1,177		364		2,712		1,072
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

The following table presents the Company’s revenues disaggregated by the geographic region to which the product is delivered or licensee is located (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
APAC	$	8,523	$	7,152	$	23,474	$	22,435
North America		4,197		2,109		8,623		5,033
EMEA		2,075		859		4,826		4,586
Total revenue	$	14,795	$	10,120	$	36,923	$	32,054

XML

Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2021

Balance Sheet Components

Schedule of Inventory

Inventory consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Raw materials	$	356	$	329
Work-in-process		5,084		4,910
Finished goods		1,228		482
Total inventory	$	6,668	$	5,721

Schedule of accrued liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30,		December 31,
	2021		2020
Payroll-related expenses	$	1,994	$	1,274
Inventory		266		416
Other		263		542
Total accrued liabilities	$	2,523	$	2,232

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2021

Leases

Schedule of Undiscounted future non-cancellable lease payments

The undiscounted future non-cancellable lease payments under the Company’s operating leases were as follows (in thousands):

As of September 30, 2021	Amount
2021	$	391
2022		861
2023		68
Total lease payments		1,320
Less: imputed interest		(41)
Total operating lease liabilities		1,279
Less: current portion of operating lease liabilities		(1,011)
Total operating lease liabilities, net of current portion	$	268

Schedule of supplemental information

	September 30,		December 31,
	2021		2020
Weighted-average remaining lease term (years)	1.15		1.74
Weighted-average discount rate	6.00	%	6.00	%

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2021

Debt

Summary of debt

The carrying value of the Company’s 2019 Credit Facility as of September 30, 2021 was as follows (in thousands):

	Current		Long-Term
	Portion		Debt		Total
Credit Facility	$	3,400	$	2,220	$	5,620
Unamortized debt discounts		(36)		(120)		(156)
Net carrying value	$	3,364	$	2,100	$	5,464

The carrying value of the Company’s 2019 Credit Facility as of December 31, 2020 was as follows (in thousands):

	Current		Long-Term
	Portion		Debt		Total
Credit Facility	$	4,400	$	4,020	$	8,420
Unamortized debt discounts		(158)		(272)		(430)
Net carrying value	$	4,242	$	3,748	$	7,990

Summary of principal repayments of credit facility

The table below includes the principal repayments due under the 2019 Credit Facility (in thousands):

	Principal Repayment as of September 30, 2021
2021 (three remaining months)		600
2022		3,400
2023		1,620
Total principal repayments	$	5,620

XML

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2021

Stock-Based Compensation

Summary of stock option activity

		Options Outstanding
			Weighted-		Weighted-
	Options and		Average		Average	Aggregate
	Awards		Exercise		Remaining	Intrinsic
	Available for	Number of	Price Per		Contractual	Value
	Grant	Options	Share		Life (years)	(In thousands)
Balance—December 31, 2020	179,219	2,272,905	$	5.58	7.9	$	1,640
Authorized	1,120,946
RSUs granted	(517,564)
RSUs cancelled/forfeited	108,581
Options granted	(744,978)	744,978	$	5.60
Options exercised	—	(104,743)	$	2.94		$	346
Options cancelled/forfeited	897,471	(916,911)	$	6.49
Balance—September 30, 2021	1,043,675	1,996,229	$	5.30	8.3	$	2,951
Options exercisable—September 30, 2021		760,979	$	6.01	6.8	$	895

Schedule of restricted stock unit activity

	RSUs Outstanding
		Weighted-
		Average
	Number of	Grant Date
	Restricted Stock	Fair Value Per
	Units	Share
Balance—December 31, 2020	416,742	$	4.89
Granted	517,564	$	5.51
Vested	(362,438)	$	5.62
Cancelled/forfeited	(108,581)	$	4.75
Balance—September 30, 2021	463,287	$	5.05

XML

Net Income (Loss) Per Common Share (Tables)

9 Months Ended

Sep. 30, 2021

Net Income (Loss) Per Common Share

Computation of basic and diluted net income (loss) per share

The following tables set forth the computation of basic and diluted net income (loss) per share attributable to common stockholders (in thousands, except share and per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Numerator:
Net income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Denominator:
Weighted-average common shares outstanding used to calculate net income (loss) per common share, basic		19,511,132		18,942,163		19,296,241		18,705,149
Net income (loss) per common share, basic	$	0.05	$	(0.21)	$	0.03	$	(0.37)

	Three Months Ended September 30,				Nine Months Ended September 30,
	September 30,				September 30,
	2021		2020		2021		2020
Numerator:
Net income (loss)	$	880	$	(3,895)	$	676	$	(6,921)
Denominator:
Weighted-average common shares outstanding used to calculate net income (loss) per common share, basic		19,511,132		18,942,163		19,296,241		18,705,149
Effect of dilutive		401,786		—		491,648		—
Weighted-average common shares outstanding used to calculate net income (loss) per common share, diluted		19,912,918		18,942,163		19,787,889		18,705,149
Net income (loss) per common share, diluted	$	0.04	$	(0.21)	$	0.03	$	(0.37)

Schedule of potentially dilutive securities excluded from diluted net loss per common share

	Three Months Ended September 30,		Nine Months Ended September 30,
	2021	2020	2021	2020
Options to purchase common stock	1,251,209	2,300,452	1,277,088	2,300,452
RSUs	6,437	458,324	28,389	458,324
Common stock warrants	9,375	49,336	9,375	49,336
ESPP	14,031	—	28,078	—
Total	1,281,052	2,808,112	1,342,930	2,808,112

XML

Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts receivable
Trade accounts receivable	$ 10,500	$ 7,590
Unbilled accounts receivable	344	255
Allowance for product returns and price concessions	(215)	(238)
Accounts receivable, net	$ 10,629	$ 7,607

XML

Summary of Significant Accounting Policies - Schedule of Revenue and Accounts Receivable for Each Significant Customer (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Revenue [Member] | Customer A [Member]
Concentration risk
Concentration risk percentage	17.00%	38.00%	14.00%	32.00%
Revenue [Member] | Customer B [Member]
Concentration risk
Concentration risk percentage	13.00%		20.00%
Revenue [Member] | Customer B [Member] | Maximum [Member]
Concentration risk
Concentration risk percentage		10.00%		10.00%
Revenue [Member] | Customer C [Member] | Maximum [Member]
Concentration risk
Concentration risk percentage	10.00%	10.00%	10.00%	10.00%
Accounts Receivable, net [Member] | Customer A [Member]
Concentration risk
Concentration risk percentage			21.00%		29.00%
Accounts Receivable, net [Member] | Customer B [Member]
Concentration risk
Concentration risk percentage			31.00%		25.00%
Accounts Receivable, net [Member] | Customer C [Member]
Concentration risk
Concentration risk percentage			12.00%
Accounts Receivable, net [Member] | Customer C [Member] | Maximum [Member]
Concentration risk
Concentration risk percentage					10.00%

XML

Summary of Significant Accounting Policies - Schedule of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value
Total assets measured at fair value	$ 14,657	$ 14,669
Warrant liability	36	31
Total liabilities measured at fair value	36	31
Level 1 [Member]
Fair Value
Total assets measured at fair value	14,657	14,669
Level 3 [Member]
Fair Value
Warrant liability	36	31
Total liabilities measured at fair value	36	31
Money Market Funds [Member]
Fair Value
Money market funds	14,657	14,669
Money Market Funds [Member] | Level 1 [Member]
Fair Value
Money market funds	$ 14,657	$ 14,669

XML

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Summary of Significant Accounting Policies
Cost of sales	$ 6,347	$ 7,791	$ 15,294	$ 19,183

XML

Revenue - Disaggregated by Sales Channel (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue
Revenue	$ 14,795	$ 10,120	$ 36,923	$ 32,054
Distributor
Disaggregation of Revenue
Revenue	9,143	5,385	24,644	18,952
Non-distributor
Disaggregation of Revenue
Revenue	$ 5,652	$ 4,735	$ 12,279	$ 13,102

XML

Revenue - Disaggregated by Timing of Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue
Revenue	$ 14,795	$ 10,120	$ 36,923	$ 32,054
Point in time
Disaggregation of Revenue
Revenue	13,618	9,756	34,212	30,982
Over time
Disaggregation of Revenue
Revenue	$ 1,177	$ 364	$ 2,711	$ 1,072

XML

Revenue - Disaggregated by Type (Details) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2021 USD ($) patent	Sep. 30, 2021 USD ($) patent	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)
Disaggregation of Revenue
Revenue			$ 14,795	$ 10,120	$ 36,923	$ 32,054
Product sales
Disaggregation of Revenue
Revenue			12,037	9,577	31,292	30,139
Royalties
Disaggregation of Revenue
Revenue			274	179	1,612	843
Patents
Disaggregation of Revenue
Revenue			1,307		1,307
Number of patents sold | patent		5
Amount to be received from sale of patents		$ 5,250	5,250		5,250
Patents | Patents assigned in September 2021
Disaggregation of Revenue
Revenue		$ 1,300
Number of patents sold | patent		2
Patents | Patents assigned in October 2021
Disaggregation of Revenue
Revenue	$ 3,950
Number of patents sold | patent	3
Other revenue
Disaggregation of Revenue
Revenue			$ 1,177	$ 364	$ 2,712	$ 1,072

XML

Revenue - Disaggregated by Geographic Region (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021 USD ($) region	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) region	Sep. 30, 2020 USD ($)
Disaggregation of Revenue
Number of primary geographic regions | region	3		3
Revenue	$ 14,795	$ 10,120	$ 36,923	$ 32,054
APAC
Disaggregation of Revenue
Revenue	2,075	859	4,826	4,586
North America
Disaggregation of Revenue
Revenue	8,523	7,152	23,474	22,435
EMEA
Disaggregation of Revenue
Revenue	$ 4,197	$ 2,109	$ 8,623	$ 5,033

XML

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory
Raw materials	$ 356	$ 329
Work-in-process	5,084	4,910
Finished goods	1,228	482
Total inventory	$ 6,668	$ 5,721

XML

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accrued liabilities
Payroll-related expenses	$ 1,994	$ 1,274
Inventory	266	416
Other	263	542
Total accrued liabilities	$ 2,523	$ 2,232

XML

Balance Sheet Components - Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Deferred Revenue
Revenue	$ 14,795		$ 10,120	$ 36,923	$ 32,054
Deferred licensing revenue	1,382			1,382
RAD-Hard product
Deferred Revenue
Total amount of consideration to be received				6,500
Revenue	900			2,300
Amount of consideration received	700	$ 3,000
Deferred licensing revenue	$ 1,400			$ 1,400

XML

Leases (Details) $ in Thousands	2 Months Ended
	Oct. 31, 2021 USD ($) lease	Sep. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Future operating lease payments
2021		$ 391
2022		861
2023		68
Total lease payments		1,320
Less: imputed interest		(41)
Total operating lease liabilities		1,279
Less: current portion of operating lease liabilities		(1,011)	$ (1,508)
Total operating lease liabilities, net of current portion		$ 268	$ 903
Other lease information
Weighted-average remaining lease term (years)		1 year 1 month 24 days	1 year 8 months 26 days
Weighted-average discount rate		6.00%	6.00%
Number of new leases entered into | lease	2
Period of time prior to maturity of lease to extend lease	12 months
Minimum
Other lease information
Monthly escalating lease payments for the new leases	$ 13
Maximum
Other lease information
Monthly escalating lease payments for the new leases	$ 39

XML

Debt - Credit Facility (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 22, 2021	Aug. 05, 2019	Jul. 31, 2020	Jun. 30, 2020	Aug. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jul. 15, 2020	Jul. 31, 2019
Debt
Common stock, par value						$ 0.0001		$ 0.0001		$ 0.0001	$ 0.01
Exercise of warrants (in shares)	21,463
Outstanding balance						$ 1,000		$ 1,000
Other (expense) income						(8)	$ (3)	(35)	$ 60
SVB Credit Facility [Member]
Debt
Repayment of credit facility					$ 800
Principal amount												$ 8,000
2019 Credit Facility
Debt
Number of shares the warrant can be converted to		9,375									21,500
Warrant exercise price		$ 8.91
Amount bank could receive if takes the option to put the warrants upon expiration or a liquidity event		$ 50
Fair value of warrants											$ 152
Principal amount						5,620		5,620		$ 8,420
Outstanding balance						4,600		4,600
Other (expense) income						$ 0	$ (5)	$ (5)	$ (2)
2019 Credit Facility | Prime Rate [Member]
Debt
Effective interest rate						3.75%		3.75%
2019 Credit Facility - Revolving Line Of Credit
Debt
Loan agreement amount			$ 5,000
Agreement term			2 years
Interest rate, basis spread percentage			1.50%
Effective interest rate			4.75%	6.75%		10.18%		10.18%
Commitment fee (as a percentage)					1.60%
Termination fee (as a percentage)			1.00%
Unused facility fee (as a percentage)			0.125%
Debt amount					$ 2,000
Remaining availability					$ 3,000
2019 Credit Facility - Revolving Line Of Credit | Prime Rate [Member] | Minimum [Member]
Debt
Interest rate, basis spread percentage			4.75%
Effective interest rate						4.75%		4.75%
2019 Credit Facility - Term Loan
Debt
End-of-term fee (as a percent)			7.00%
Agreement term			46 months
Effective interest rate			3.75%	4.75%		7.85%		7.85%
Prepayment fee (as a percentage)			2.00%
Debt amount			$ 6,000
Number of months of interest only payment			16 months	12 months
Number of months of equal principal payments plus accrued interest			30 months
2019 Credit Facility - Term Loan | Prime Rate [Member]
Debt
Interest rate, negative basis spread percentage			0.75%
Effective interest rate			3.75%

XML

Debt - Carrying Value (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt
Net carrying value of debt, Current Portion	$ 3,364	$ 4,242
Net carrying value of debt, Long-term debt	2,100	3,748
2019 Credit Facility
Debt
Debt, Current Portion	3,400	4,400
Less: Debt issuance costs, Current Portion	(36)	(158)
Net carrying value of debt, Current Portion	3,364	4,242
Debt, including end of term fee, Long-term debt	2,220	4,020
Less: Unamortized debt discounts, Long-term debt	(120)	(272)
Net carrying value of debt, Long-term debt	2,100	3,748
Total principal repayments	5,620	8,420
Less: Discount attributable to warrants, end of term fee and debt issuance costs, Total	(156)	(430)
Net carrying value of debt, Total	$ 5,464	$ 7,990

XML

Debt - Summary of Principal Repayments of 2019 Credit Facility (Details) - 2019 Credit Facility - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt
2021	$ 600
2022	3,400
2023	1,620
Total principal repayments	$ 5,620	$ 8,420

XML

Stockholders' Equity - (Details) - At-the-Market Sales Agreement - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Aug. 31, 2019	Sep. 30, 2020
Common stock reserved
Maximum amount of shares for offering	$ 25.0
Maximum commission percentage	3.00%
Net proceeds		$ 2.1
Number of shares sold		468,427

XML

Stock-Based Compensation - Summary of Options and Awards Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Stock-based compensation
Options and Awards Available for Grant, Outstanding, Beginning balance	179,219
Options and Awards Available for Grant, Options authorized	1,120,946
Options and Awards Available for Grant, RSUs granted	(517,564)
Options Available for Grant, RSUs cancelled/forfeited	108,581
Options and Awards Available for Grant, Options granted	(744,978)
Options and Awards Available for Grant, Options cancelled/forfeited	897,471
Options and Awards Available for Grant, Outstanding, Ending balance	1,043,675	179,219
Number of Options, Outstanding, Beginning balance	2,272,905
Number of Options, Options granted	744,978
Number of Options, Options exercised	(104,743)
Number of Options, Options cancelled/forfeited	(916,911)
Number of Options, Outstanding, Ending balance	1,996,229	2,272,905
Number of Options, exercisable	760,979
Weighted - Average Exercise Price Per Share, Options outstanding, Beginning balance | $ / shares	$ 5.58
Weighted - Average Exercise Price Per Share, Options granted | $ / shares	5.60
Weighted - Average Exercise Price Per Share, Options exercised | $ / shares	2.94
Weighted - Average Exercise Price Per Share, Options cancelled/forfeited | $ / shares	6.49
Weighted - Average Exercise Price Per Share, Options outstanding, Ending balance | $ / shares	5.30	$ 5.58
Weighted - Average Exercise Price Per Share, Options exercisable | $ / shares	$ 6.01
Weighted - Average Remaining Contractual Life, Options outstanding	8 years 3 months 18 days	7 years 10 months 24 days
Weighted - Average Remaining Contractual Life, Options exercisable	6 years 9 months 18 days
Aggregate Intrinsic Value, Options outstanding | $	$ 2,951	$ 1,640
Aggregate Intrinsic Value, Options exercised | $	346
Aggregate Intrinsic Value, Options exercisable | $	$ 895

XML

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended						9 Months Ended
	Jan. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Compensation
Total grant date fair value of options vested		$ 178			$ 438			$ 711	$ 1,800
Number of Options, Options cancelled/forfeited								916,911
Shares available for future issuance (in shares)		1,043,675						1,043,675		179,219
Value of share issued			$ 92	$ 364	$ 379	$ 827	$ 315
Weighted-average exercise price (per share)		$ 5.30						$ 5.30		$ 5.58
Number of stock options granted (in shares)								744,978
Options remained outstanding		1,996,229						1,996,229		2,272,905
Employees [Member]
Share-based Compensation
Weighted-average grant date fair value of options granted		$ 3.59			$ 3.62			$ 3.58	$ 1.71
2016 Employee Stock Purchase Plan [Member]
Share-based Compensation
Increase in number of shares reserved for issuance (in shares)	190,315
Shares available for future issuance (in shares)		684,996						684,996
Value of share issued		$ 92			$ 50			$ 92	$ 50
Number of shares issued (in shares)		32,186			22,474			32,186	22,474
Prior Stock Based Compensation Plan
Share-based Compensation
Number of Options, Options cancelled/forfeited								19,440

XML

Stock-Based Compensation - Restricted Stock Units (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2021 USD ($) $ / shares shares
Weighted Average Exercise Price Per Share
Unrecognized stock-based compensation expense | $	$ 3.5
Unrecognized compensation expense, weighted-average period expected to be recognized	3 years
RSUs
Number of Restricted Stock Units
Balance, beginning of period | shares	416,742
Granted | shares	517,564
Vested | shares	(362,438)
Cancelled/forfeited | shares	(108,581)
Balance, end of period | shares	463,287
Weighted Average Exercise Price Per Share
Balance, beginning of period (price per share) | $ / shares	$ 4.89
Granted (price per share) | $ / shares	5.51
Vested (price per share) | $ / shares	5.62
Cancelled/forfeited (price per share) | $ / shares	4.75
Balance, end of period (price per share) | $ / shares	$ 5.05
2016 Employee Incentive Plan [Member] | RSUs
Weighted Average Exercise Price Per Share
Unrecognized stock-based compensation expense | $	$ 1.9
Unrecognized compensation expense, weighted-average period expected to be recognized	2 years 2 months 12 days

XML

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021 USD ($)
Stock-Based Compensation
Unrecognized stock-based compensation expense	$ 3.5
Unrecognized compensation expense, weighted-average period expected to be recognized	3 years

XML

Significant Agreements (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended			9 Months Ended		37 Months Ended
	Oct. 17, 2014	Sep. 30, 2018	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Joint development agreement
Project costs			$ 3,105	$ 2,579		$ 8,901	$ 8,383
Revenue			14,795	10,120		36,923	32,054
Common Stock [Member]
Joint development agreement
Number of shares sold					468,427
Royalties
Joint development agreement
Revenue			$ 274	$ 179		1,612	$ 843
Joint Development Agreement [Member] | Global Foundries, Inc. [Member]
Joint development agreement
Period of possession of exclusive right to manufacture after qualification of device	3 years
Period of possession of exclusive right to manufacture after completion of device development work	4 years
Collaborative Agreement | Silterra
Joint development agreement
Non-recurring engineering cost obligation		$ 1,000
JCA costs						$ 0		$ 600

XML

Net Income (Loss) Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net income (loss)	$ 880	$ 256	$ (460)	$ (3,895)	$ (1,294)	$ (1,732)	$ 676	$ (6,921)
Net income (loss) per common share, basic
Weighted average common shares used to compute net income (loss) per common share attributable to common stockholders, basic	19,511,132			18,942,163			19,296,241	18,705,149
Net income (loss) per share attributable to common share, basic	$ 0.05			$ (0.21)			$ 0.03	$ (0.37)
Net income (loss) pe common share, diluted
Effect of dilutive	401,786						491,648
Weighted-average common shares outstanding used to calculate net income (loss) per common share, diluted	19,912,918			18,942,163			19,787,889	18,705,149
Net income (loss) per share attributable to common stockholders, diluted	$ 0.04			$ (0.21)			$ 0.03	$ (0.37)

XML

Net Income (Loss) Per Common Share - Schedule of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Common Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities
Potentially dilutive securities excluded from diluted net loss per common share	1,281,052	2,808,112	1,342,930	2,808,112
Options to Purchase Common Stock [Member]
Antidilutive Securities
Potentially dilutive securities excluded from diluted net loss per common share	1,251,209	2,300,452	1,277,088	2,300,452
RSUs
Antidilutive Securities
Potentially dilutive securities excluded from diluted net loss per common share	6,437	458,324	28,389	458,324
2016 Employee Stock Purchase Plan [Member]
Antidilutive Securities
Potentially dilutive securities excluded from diluted net loss per common share	14,031		28,078
Common stock warrants | Common Stock Subject to Repurchase [Member]
Antidilutive Securities
Potentially dilutive securities excluded from diluted net loss per common share	9,375	49,336	9,375	49,336